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Thesis Abstract 
 
 
This thesis reports that checkpoint adaptation occurs in human brain 
cancer cells.  M059K cells, after treatment with camptothecin (CPT), recruited γ-
histone H2AX, phosphorylated Chk1 and arrested in the G2 phase.  Strikingly, 
cells escaped the checkpoint, became rounded and entered mitosis as measured by 
phospho-histone H3 signals.  Lamin A/C immunofluorescence microscopy 
revealed that 48% of the cells that survived checkpoint adaptation contained 
micronuclei.  These data suggest that brain cancer cells undergo checkpoint 
adaptation and may have an altered genome.  This thesis also explored if 
phosphatases participate in checkpoint adaptation.  Human colon cancer cells 
were treated with CPT and the PP2A inhibitor cantharidin.  Following treatment 
the cells became rounded and 65% were positive for phospho-histone H3 signals 
indicating that cantharidin caused cells to be in mitosis following CPT treatment.  
These data suggest that PP2A might have a role in checkpoint adaptation, or 
participate in a pathway that bypasses checkpoint adaptation.  
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Chapter 1 
1. Literature Review  
This thesis examines checkpoint adaptation in brain cancer cells.  A 
comprehensive explanation of the eukaryotic cell cycle, DNA damage and 
checkpoint adaptation is provided, and how these topics relate to brain cancer will 
be illustrated.   
 
1.1. The Cell Cycle 
Progression through the cell cycle is a carefully regulated and coordinated 
process.  Cell cycle regulation has been conserved from yeast to mammals and 
ensures the formation of genetically identical progeny cells (George, 2003).  Not 
surprisingly, defects in cell cycle regulation are a common cause of abnormal 
proliferation and the genomic instability of cancer cells (Cooper and Hausman, 
2009).  Studies of the cell cycle and cancer have become closely interconnected.  
In eukaryotic cells, the cell cycle is made up of two main phases: 
interphase and mitotic phase (M phase).  Interphase, taking up nearly 95% of the 
cell cycle is the phase during which both cell growth and DNA replication occur 
in sequential stages in preparation for cell division (Cooper and Hausman, 2009).  
Interphase is composed of three stages: Gap 1 phase (G1 phase), Synthesis phase 
(S phase), and Gap 2 phase (G2 phase) (Norbury and Nurse, 1992).  G1 phase 
corresponds to the interval between M phase and the initiation of DNA 
replication.  During G1 phase, the cell is metabolically active and continuously 
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growing.  G1 phase is followed by S phase during which DNA replication takes 
place.  The purpose of S phase is to replicate DNA into identical, semi-conserved 
chromosomes, which will be passed down to daughter cells.  The completion of 
DNA synthesis is followed by G2 phase, during which cell growth continues and 
proteins are synthesized in preparation for mitosis.   
M phase of the cell cycle corresponds to mitosis ending in cell division.  
Mitosis is characterized by the following processes: chromatin condensation and 
nuclear envelope breakdown, chromosome alignment, sister chromatid separation 
and migration to opposite poles of the cell, reformation of the nuclear membrane 
forming two nuclei, followed by chromosome decondensation (Rieder and 
Khodjakov, 2003).  Chromosome decondensation occurs simultaneously with or 
is immediately followed by cytokinesis.  Cytokinesis separates the cytoplasm, 
organelles and nuclei into two identical daughter cells, signifying completion of 
M phase.  Mitosis is also characterized by morphological changes such as cell 
rounding, making them easily distinguishable from flattened interphase cells, as 
well as phosphorylation of histones, including histone H3 on serine 10 (Harris, 
1973; Hendzel et al., 1997).  These characteristics make it possible to follow cells 
as they exit from G2 phase, enter into mitosis and subsequently exit from mitosis 
(Juan et al., 1998).      
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1.1.1. Cell Cycle Regulators  
Progression through the cell cycle is governed by a number of control 
points and regulators to ensure efficient and accurate cell growth, DNA 
replication and cell division.  Some of these regulators are extracellular signals, 
such as nutrients and growth factors; whereas, a large number of them are 
intracellular proteins (Hartwell and Kastan, 1994).  A subset of these intracellular 
protein regulators are the cyclin-dependent kinases (Cdks) and their protein 
regulatory partners the cyclins (Kastan and Bartek, 2004).  Cyclins have no 
enzymatic activity, but are required to facilitate the catalytic function of the Cdks.  
Within the cell there are at least eight catalytic Cdks and regulatory cyclins 
working together to ensure proper regulation throughout the cell cycle (Nigg, 
1995).  For example, the Cdk4/cyclin D complex functions early in G1 phase in 
response to growth factors, whereas, the Cdk2/cyclin E complex regulates 
transition to S phase.  
Cdk1/cyclin B is a protein complex that is important in the regulation of 
mitosis.  This complex acts by controlling entry into and exit from the M phase of 
the cell cycle and is composed of two protein subunits: Cdk1 and cyclin B (Pines 
and Hunter, 1990).  These protein subunits have two mechanisms by which they 
control entry and exit of the M phase:  1) Oscillations in cyclin B levels during the 
cell cycle control Cdk1 activity, thereby controlling mitotic entry and exit (Evans 
et al., 1983).  Cyclin B levels rise during G2 until a peak is reached during 
mitosis.  Levels then fall at the middle of mitosis, due to cyclin B degradation, 
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resulting in conclusion and exit from mitosis.  2) Cdk1/cyclin B complex activity 
is also regulated by the phosphorylation status of Cdk1, which is controlled by 
protein phosphatases and kinases (Forsburg and Nurse, 1991).  Once the Cdk1 
and cyclin B complex forms, it undergoes a conformational change that increases 
the accessibility of the Cdk1 residue threonine 161 (Thr161).  Cdk1 is then 
phosphorylated at Thr161 by cyclin-dependent kinase (Cdk)-activating kinase 
(CAK) (Norbury et al., 1991).  This phosphorylation results in a change in protein 
structure that allows ATP access to the catalytic site of Cdk1.  However, this 
activating Thr161 phosphorylation does not activate the complex due to inhibitory 
phosphorylations on threonine 14 (Thr14) and tyrosine 15 (Tyr15) of Cdk1.  
These sites are phosphorylated by the protein kinases Myt1 and Wee1, 
respectively (Parker and Piwnica-Worms, 1992; Mueller et al., 1995).  For entry 
into mitosis, the inhibitory phosphorylations are removed by the Cdc25 
phosphatases, thereby exposing the ATP binding site of Cdk1 (Sebastian et al., 
1993).  The dephosphorylation by Cdc25 phosphatases results in Cdk1/cyclin B 
complex activation, thereby triggering entry into mitosis.  This dual control 
mechanism is one example of the many cell cycle regulators, and mechanisms 
within each regulator, working to ensure precise and properly coordinated cell 
cycle progression.         
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1.1.2. Cell Cycle Checkpoints 
In addition to cell cycle regulators, the cell cycle is also controlled by a 
series of control points known as cell cycle checkpoints (Hartwell and Weinert, 
1989).  Cell cycle checkpoints ensure the fidelity of cell division by preventing 
entry into the next phase of the cell cycle until the events of the preceding phase 
have been completed.  Checkpoints also prevent progression through the cell 
cycle if the genome is damaged or improperly structured (Kastan and Bartek, 
2004; Bartek and Lukas, 2007).  This is accomplished through four main cell 
cycle checkpoints, one is called the spindle assembly checkpoint and the other 
three are called DNA damage checkpoints (Abraham, 2001).        
The spindle assembly checkpoint occurs toward the end of mitosis and 
monitors spindle structure as well as the alignment of chromosomes on the mitotic 
spindle, thus ensuring that a complete set of chromosomes is distributed 
accurately to the daughter cells (Rudner and Murray, 1996).  Failure of one or 
more chromosomes to align properly, or the occurrence of inaccurate spindle 
structure, will be detected at the spindle assembly checkpoint resulting in a cell 
cycle arrest in metaphase of mitosis (Abraham, 2001).  This M phase arrest is 
released after proper chromosome alignment or when correct spindle structure has 
been restored, at which point the cell progresses from metaphase to anaphase. 
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1.2. DNA Damage Checkpoints 
When dividing cells contain damaged DNA they initiate a response named 
the DNA damage checkpoint
 
(Hartwell and Weinert, 1989; Carr, 2002).  This 
checkpoint ensures genome fidelity by arresting cell cycle progression to provide 
time for repair, thereby preventing proliferation of cells with damaged DNA 
(Toczyski et al., 1997; van Vugt et al., 2005).  A DNA damage checkpoint 
functions in each of the three stages of interphase (Cooper and Hausman, 2009).  
The G1 checkpoint will halt cell cycle progression in the presence of damaged 
DNA to allow time for DNA repair before the cell enters S phase (Abraham, 
2001).  This G1 checkpoint prevents damaged DNA from being replicated in the 
synthesis phase.  The S phase checkpoint not only provides continual monitoring 
of the integrity of DNA to ensure damaged DNA is repaired before replication, 
but it also promotes the repair of errors that occur during DNA replication.           
 
1.2.1. G2 DNA Damage Checkpoint 
The G2 DNA damage checkpoint is one of the main processes under 
investigation in this thesis and therefore, a comprehensive understanding of how it 
functions is essential to this discussion.  The G2 DNA damage checkpoint is 
present in the G2 phase of the cell cycle and prevents the initiation of mitosis in 
cells that contain damaged DNA (Melo and Toczyski, 2002).   
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1.2.1.1. Activation of the G2 DNA Damage Checkpoint 
The G2 DNA damage checkpoint is a molecular system composed of 
sensors, transducers and effectors.  Collectively, these create a phosphorylation 
cascade that ultimately results in a G2 phase arrest of the cell cycle (Melo and 
Toczyski, 2002).  The type of damaged DNA, either DNA double stranded break 
(DSB) or DNA single stranded break, will result in the activation of either the 
ataxia telangiectasia mutated (ATM) or ataxia telangiectasia mutated Rad 3-
related (ATR) kinases, respectively (Smith et al., 2010).  Both ATM and ATR are 
protein kinases belonging to the phosphoinositide 3-kinase related kinases 
(PIKKs) family, whose activation initiates the checkpoint pathway.  DSB damage 
is recognized by the Mre-11-Rad50-Nbs1 (MRN) complex, which ultimately 
results in ATM pathway activation.  Whereas, DNA single stranded breaks result 
in the rapid accumulation of the single stranded binding protein, Replication 
Protein A (RPA), which results in the activation of the ATR pathway (Harper and 
Elledge, 2007).     
In response to damaged DNA, ATM and ATR phosphorylate Checkpoint 
kinase 2 (Chk2) and Checkpoint kinase 1 (Chk1) substrates, respectively (Jazayeri 
et al., 2006).  ATM and ATR also phosphorylate histone H2AX at Ser139, 
denoted γ-H2AX following phosphorylation (Rogakou et al., 1998; Burma et al., 
2001; Ward and Chen, 2001).  This phosphorylation occurs within minutes of 
DNA damage and thus H2AX phosphorylation on Ser139 has become a standard 
marker for the presence of damaged DNA (Rogakou et al., 1998; Bonner et al., 
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2008).  This phosphorylation is required for DNA repair, and is removed by the 
phosphatase PP2A once repair has been completed (Chowdhury et al., 2005).  
Upon detection of DSB damage, the MRN complex recruits ATM to the site of 
the DSB resulting in ATM activation.  Once ATM has been activated, there is the 
initiation of a sequence of events, including DSB resection, which results in single 
stranded DNA (ssDNA) formation (Jazayeri et al., 2006).  This ssDNA in turn 
facilitates the recruitment of RPA.  The prolonged presence of RPA at a site 
causes the recruitment of the heterodimer ATR interacting protein (ATRIP) 
(Burrows and Elledge, 2008).  ATR complexes with its protein partner ATRIP 
enabling the complex to bind to ssDNA (Liu et al., 2000; Zhao and Piwnica-
Worms, 2001).  The now active ATR, with assistance from the adaptor protein 
claspin, phosphorylates the signal transducer, Chk1 on serines 317 and 345 
thereby activating it (Figure 1).  Checkpoint kinases inhibit entry into mitosis 
through two mechanisms: 1) upregulation of Wee1 kinase and 2) downregulation 
of the Cdc25 phosphatases (Sancar et al., 2004).  These two mechanisms work in 
unison to control Cdk1/cyclin B complex activity through Cdk1 inhibitory 
phosphorylations, and inhibition of the dephosphorylation mechanisms, 
respectively.  Upon ATR phosphorylation, the now active Chk1 phosphorylates 
Cdc25C, a protein phosphatase, on serine 216 (Ser216), rendering Cdc25C 
inactive.  In mammalian cells, three isoforms of Cdc25 have been identified: 
Cdc25A, Cdc25B and Cdc25C (Boutros et al., 2006).  By knockout studies in 
mice, Cdc25C has been identified as the main effector of the G2/M checkpoint  
 9 
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pathway.  Upon Ser216 phosphorylation, the Cdc25C phosphatase binds to the 
protein unit 14-3-3, and becomes sequestered in the cytoplasm where it is 
degraded by the ubiquitin-proteasome pathway (Margolis et al., 2003; Sancar et 
al., 2004).  With Cdc25C sequestered and degraded, there is an accumulation of 
inactive phosphorylated Cdk1, resulting in a G2 phase cell cycle arrest (Toczyski 
et al., 1997; Bartek and Lukas, 2007).   
 
1.3. DNA Damaging Agents  
Genotoxic agents damage the DNA of a cell, which if not repaired, may 
result in cell death
 
(Bartek and Lukas, 2007).  Current cancer treatments, such as 
chemotherapy or radiation, exploit the action of genotoxic agents in an attempt to 
kill cancer cells.  In fact, the majority of cancer patients will be exposed to 
genotoxic agents over the course of their treatment (Siegel et al., 2011).  An 
example of a genotoxic agent that is used in anti-cancer treatment is camptothecin 
(CPT), which is an active ingredient used in chemotherapy.  The 
pharmacokinetics of CPT and its derivatives have been investigated extensively in 
humans, providing valuable information to model the genotoxic response in 
cancer cells (Pizzolato and Saltz, 2003).   The mechanism of action for CPT is 
topoisomerase 1 (Topo1) inhibition.  Topo1 is an enzyme that removes DNA 
supercoils that occur during transcription and DNA replication due to the 
intertwined nature of the double helix (Roca, 1995).  Normally Topo1 induces 
nicks or single stranded DNA cleavages in the DNA backbone to release torsional 
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strain.  However if CPT is present, CPT binds to Topo1 and DNA, resulting in the 
formation of a ternary complex (Hsiang et al., 1989).  This ternary complex 
stabilizes the covalent binding of Topo1 to the 3’ end of the broken DNA 
preventing the religation of the nicked strand and the release of the enzyme.  
When this stabilized complex encounters a replication fork, the single stranded 
breaks are converted into irreversible double stranded breaks (Beretta and Zunino, 
2007).  
 
1.4. Outcomes of Initiating the G2 DNA Damage Checkpoint 
Until recently, there were thought to be two main outcomes of the DNA 
damage checkpoint, depending on the severity of the damage (Zhou and Elledge, 
2000).  One outcome is cell cycle arrest, DNA repair and re-entry into mitosis, a 
process known as checkpoint recovery (Bartek and Lukas, 2007).  The second 
outcome being the inability for DNA to be repaired, resulting in the initiation of 
the apoptosis pathway that ends with programmed cell death.  However in 1997, 
Toczyski et al. introduced a third outcome following initiation of the DNA 
damage checkpoint in which the cells, after a G2 phase cell cycle arrest, enter into 
mitosis regardless of the presence of damaged DNA (Toczyski et al., 1997).  This 
process is called checkpoint adaptation.    
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1.4.1. Checkpoint Recovery 
The DNA damage checkpoint allows time for DNA damage repair, after 
which cells can resume cell cycle progression and undergo cell division.  
Checkpoint recovery is the process by which repaired cells inactivate the DNA 
damage checkpoint and enter into mitosis (Zhou and Elledge, 2000).  Upon repair 
of damaged DNA, the DNA damage checkpoint sensors become inactivated.  
With these sensors inactive, the activation of downstream substrates is 
suppressed.  This cascade of substrate inactivation results in the cells ability to 
exit the G2 block and enter into mitosis (Clemenson and Marsolier-Kergoat, 
2009).        
 
1.4.2. Apoptosis 
Programmed cell death, or apoptosis, is a regulated form of cell death, 
which is essential for various biological events such as morphogenesis.  However, 
it is also important for the elimination of potentially harmful cells.  If a cell 
becomes damaged and cannot be repaired, the cell may undergo apoptosis (Cheng 
et al., 2011).  Regulated destruction of a cell is a complicated process, in which 
proper execution requires the coordinated activation and operation of multiple 
mechanisms.  The terminal apoptotic pathway of mammalian cells depends on the 
activation of caspases, which is a family of proteases, and their modification of 
protein substrates within the nucleus and cytoplasm (Sancar et al., 2004).  
Activation of the apoptotic pathway results in a set of morphological and 
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biochemical features, making this a distinguishable biological process.  These 
characteristics include: cell blebbing (irregular bulging), cell shrinkage, nuclear 
fragmentation, chromatin condensation and chromosomal DNA fragmentation 
(Kerr et al., 1972).  The end result of apoptosis is controlled death and removal of 
a damaged cell to prevent further damage to the multicellular organism.   
                     
1.5. Checkpoint Adaptation  
Checkpoint adaptation is a process defined by three features in cells with 
damaged DNA: 1) cell cycle arrest, 2) entry into mitosis, 3) damaged DNA in 
mitotic cells (Toczyski et al., 1997).  This process is not well understood and is 
the central theme for my thesis work. 
 
1.5.1. History of Checkpoint Adaptation 
Checkpoint adaptation was originally described in Saccharomyces 
cerevisiae in 1993 as the ability of yeast cells to divide following a checkpoint 
arrest, despite the presence of irreparable chromosome damage (Sandell and 
Zakian, 1993).  However it was not until 1997 that this surprising result was 
credited to be checkpoint adaptation (Toczyski et al., 1997).  In the 1993 study, 
yeast strains were constructed to enable a single telomere to be eliminated from 
the end of a dispensable chromosome.  The elimination of a telomere caused a cell 
cycle arrest.  However, many cells recovered from the arrest, without repairing the 
damaged chromosome, and continued replicating and segregating for as many as 
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ten cell divisions.  Further studies led to the conclusion that checkpoint adaptation 
in yeast is a process that is accompanied by loss of Rad53p checkpoint kinase 
activity and Chk1 phosphorylation (Pellicioli et al., 2001).  It was hypothesized 
that checkpoint adaptation could potentially be a beneficial process in single cell 
organisms, which may repair the damage in subsequent cell cycles (Lee et al., 
2000; Galgoczy and Toczyski, 2001).   
In 2004, checkpoint adaptation was reported to occur in Xenopus egg 
extracts in response to the DNA polymerase alpha inhibitor aphidicolin, which 
inhibits DNA synthesis (Yoo et al., 2004).  Yoo et al. reported that following a 
prolonged interphase arrest, aphidicolin-treated egg extracts underwent 
checkpoint adaptation and entered into mitosis despite the presence of 
incompletely replicated DNA.  This adaptation was accompanied by 
phosphorylation of the checkpoint mediator protein claspin, by Plx1, which 
resulted in inactivation of the Chk1 kinase.  The demonstration of checkpoint 
adaptation in multicellular eukaryotes raised interest regarding whether 
checkpoint adaptation also exists in human cells.      
In 2006, Syljuåsen et al. confirmed that checkpoint adaptation did occur in 
human cells exposed to ionizing radiation.  The paper reported two important 
conclusions: 1) Upon exposure to ionizing radiation, human U2OS osteosarcoma 
cells underwent an extended G2 phase cell cycle arrest; however, entered mitosis 
with damaged DNA and 2) Chk1 inhibition was necessary for the exit from the 
G2 checkpoint arrest.  The first of these conclusions was based on two separate 
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experiments.  Firstly, by flow cytometry it was demonstrated that the irradiated 
cells had been arrested in the G2/M phase then abrogated the checkpoint and 
progressed into G1 phase.  Secondly, they were able to show by 
immunofluorescence microscopy and phospho-ser10 histone H3 and histone γ-
H2AX staining that the irradiated cells were in mitosis with damaged DNA.  
However, they did not report what fraction of the population entered into mitosis 
with damaged DNA, therefore it was not known if checkpoint adaptation was a 
major event.  By flow cytometry and Western blotting, Syljuåsen et al. 
demonstrated that during an extended G2 phase arrest, Chk1 was active and 
phosphorylated on three distinct serine residues.  However, cells that had 
undergone checkpoint adaptation, Chk1 was dephosphorylated at Ser317/345.  
This result suggested that the exit from the prolonged IR-induced G2/M 
checkpoint was based upon the activity of Chk1 kinase.  Syljuåsen and colleagues 
speculated that most of the cells carrying damaged DNA would eventually die; 
however, some cells might survive with DNA lesions that would make them 
prone to the development of further genomic instability.  They also speculated 
that genomic instability would have implications in human cancer and could 
potentially contribute to cancer development.    
 
1.5.2. Significance of Checkpoint Adaptation  
Both the precise mechanism and biological significance of checkpoint 
adaptation are still unknown.  With the demonstration of checkpoint adaptation in 
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human cells, a number of questions and concerns have arisen regarding the 
potential effects this process may have on multicellular organisms including: 1) 
does this happen in all human cancer cells or is this specific to certain cell types? 
2) what becomes of the cells that survive checkpoint adaptation? 
It may be speculated that the biological function of checkpoint adaptation 
in vertebrates is similar to the function that has been proposed for mitotic 
catastrophe, where defective cells with irreparable damage are eliminated through 
a mitosis-linked death, distinct from apoptosis (Vitale et al., 2011).  It may also be 
speculated that checkpoint adaptation is a testimony to the resilience of life, in a 
last ditch attempt by the cell to increase its chance for survival.  Nonetheless, 
current research has shown that 2% of cells that undergo checkpoint adaptation 
survive and complete at least one round of cellular division (Kubara et al., 2012).  
It has been speculated that the cells that survive checkpoint adaptation may 
contain a highly rearranged genome and may continue to divide, potentially 
creating a progeny with a modified genome (Syljuåsen et al., 2006; Kubara et al., 
2012).  What subsequently happens to these surviving cells and their progeny 
remains largely unknown.  
Following the report of checkpoint adaptation in human cancer cells in 
2006, a number of concerns have been identified regarding the issue of cellular 
division with damaged DNA.  Firstly, mutated DNA is the molecular foundation 
for many diseases including human-cancer-susceptibility syndromes and can 
result in further genomic instability, a hallmark of cancer (Stratton et al., 2009).  
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Secondly, the most common form of cancer treatments currently used is treatment 
with DNA damaging agents (Siegel et al., 2011).  Furthermore, cancer cells often 
have defects or impaired function of their DNA damage checkpoints ( Wang et 
al., 2008; On et al., 2011). Therefore, we are currently treating cancer cells with 
agents that may result in checkpoint adaptation.  Checkpoint adaptation has also 
been suggested to be a cause of genomic instability and further carcinogenesis 
(Kastan and Bartek, 2004; Kubara et al., 2012).  Checkpoint adaptation and cells 
that survive it may then provide insight into additional cancer developments, such 
as secondary tumors that contain major genomic rearrangements (Kastan and 
Bartek, 2004; Kubara et al., 2012).  Checkpoint adaptation may also provide a 
potential explanation for the resistance of human cancer cells to genotoxic therapy 
(chemoresistance) or cancer relapse
 
(Syljuåsen et al., 2006; Wang et al., 2008; 
Kuntz and O'Connell, 2009; Kubara et al., 2012).   
 
1.5.3. Checkpoint Adaptation in Human Cells  
Studies have demonstrated aberrant mitosis in human cells following 
exposure to radiation or treatment with genotoxic compounds (Demarcq et al., 
1994; Clifford et al., 2003; Hall and Giaccia, 2006; Vakifahmetoglu et al., 2008; 
Cahuzac et al., 2010).  These studies report cells undergoing mitotic catastrophe.  
Mitotic catastrophe is a process that lacks a distinct and uniformly accepted 
definition; however, it is characterized as a form of cell death that includes 
aberrant mitosis (Vakifahmetoglu et al., 2008).  It has been suggested that 
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checkpoint adaptation may be an inducer of, or happen prior to, mitotic 
catastrophe.   
Since 2006, there have been subsequent reports of checkpoint adaptation 
in two other human cell lines, lymphocytic leukemia cells and colon carcinoma 
cells, which have demonstrated the three features outlined by Toczyski et al. 
(1997).  There have also been reports suggesting checkpoint adaptation has 
occurred in other cell lines; however, the focus of these studies was not to 
demonstrate checkpoint adaptation.  In 2008, a study was done in metastatic 
hepatocellular carcinoma (HCC) cells treated with the genotoxic alkylating agent 
cisplatin, in which an accumulation of DNA damage lesions was believed to be 
the result of checkpoint adaptation (Wang et al., 2008).  This study was done to 
understand how cell cycle pathways (particularly Plk1 and Cdc25A pathway) 
critically affect the fate of metastatic cells.  The result of the study determined that 
the metastatic HCC cells showed a defective cell checkpoint arrest, whereby cells 
continued to enter into mitosis following cisplatin treatment.  This precocious 
entry into mitosis following cisplatin treatment resulted in an accumulation of 
DNA lesions suggested to be the result of HCC cells undergoing checkpoint 
adaptation.  It was also noted in the study that although checkpoint adaptation 
often results in the elimination of excessively damaged DNA by cell death (such 
as through mitotic catastrophe), the metastatic cells used in this study 
predominantly avoided this fate, and were able to survive checkpoint adaptation 
with accumulated DNA lesions.       
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In 2011, a study was done to determine how fractionated radiation 
(smaller more frequent doses of radiation as opposed to one larger dose of 
radiation), affects the ability of lymphocytic leukemia cells (MOLT4) and normal 
human fibroblastic cells to repair induced DNA DSB (Rezacova et al., 2011).  
They reported that both lymphocytic leukemia and human fibroblastic cells were 
unable to repair all DSBs before the next radiation dose, which produced further 
DNA damage.  Interestingly, they observed that following fractionated radiation 
doses, the MOLT4 cell line experienced a time of delayed cell proliferation that 
was due to a DNA damage checkpoint arrest.  Depending on the treatment doses 
and frequencies, this delay in cell proliferation lasted anywhere from 24 h to 72 h 
as determined by cell counting and flow cytometry.  However the MOLT4 cells 
were able to abrogate the DNA damage induced arrest and enter into mitosis with 
unrepaired DSB DNA damage.  Damaged DNA was detected by γ-H2AX 
immunofluorescence and entry into mitosis was determined by an increase and 
subsequent decrease in cyclin B levels at 24 h and 48 h after the first and second 
irradiation as determined by Western blotting.  It was reported that the normal 
human fibroblastic cell line had undergone a similar process in response to 
radiation, however they did not demonstrate a delay of cell proliferation or a 
checkpoint arrest in these cells and the level of DNA damage present following 
radiation was insufficient.  Therefore further studies on normal human fibroblastic 
cells would need to be done to determine if they also undergo checkpoint 
adaptation.     
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Recent studies have demonstrated the human colon carcinoma cell line 
HT-29, which are well characterized epithelial cells, undergo checkpoint 
adaptation when treated with pharmacologically relevant concentrations of CPT 
(Kubara et al., 2012).  The results of this study demonstrated that HT-29 cells, 
following treatment with 25 nM CPT, recruit multiple γ-H2AX foci (indicating 
damaged DNA), become phosphorylated at Ser345- of Chk1 (indicating 
activation of the DNA damage checkpoint), and enter into a G2 phase arrest.  
Then starting at 40 hours following the CPT treatment nearly all the cells escape 
the G2 phase arrest and become rounded up, a morphological characteristic of 
cells in mitosis.  These rounded cells had high levels of cyclin B1, lacked Tyr15-
Cdk1 phosphorylation and were positive for phospho-ser10 histone H3, all 
markers for cells in mitosis.  It was also reported that the cells that entered into 
mitosis with damaged DNA were dephosphorylated at Ser345-Chk1, indicating a 
relationship between Chk1 dephosphorylation and checkpoint adaptation.  Video 
microscopy demonstrated that nearly 90% of CPT treated cells entered into 
mitosis before cell death, indicating that this was a major cell cycle event that 
links cell cycle arrest to cell death.  However, it was also reported that although 
nearly all of the cells that entered into mitosis with damaged DNA died, 2% of 
these cells survived.  Figure 2 is a model proposed by Kubara et al. on the steps 
required for checkpoint adaptation after treatment with genotoxic agents.   
Using ataxia telangiectasia (A-T) cells, a cell line that has defects in both 
checkpoint arrest and DSB repair, a 2007 study proposed a threshold hypothesis  
 21 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
 
for the activation and release of the G2 checkpoint (Deckbar et al., 2007).  This 
hypothesis suggested that a threshold level of radiation induced DSB is needed to 
activate and maintain the G2 checkpoint.  In 2011, a study explored the potential 
of a DNA damage threshold in human cells as a determinant for DNA damage 
checkpoint activation and checkpoint adaptation (Tkacz-Stachowska et al., 2011).  
To do this, individual cells from human fibroblasts and U2OS osteosarcoma cells 
were irradiated and examined for checkpoint activation and release based on γ-
H2AX foci and phospho-histone H3 staining.  The results of the study indicated 
that the number of γ-H2AX foci varied between individual cells for all radiation 
doses and times.  This result suggests that the amount of damaged DNA needed to 
activate and maintain the G2 checkpoint varies between single cells within a cell 
population, thus the checkpoint, and checkpoint adaptation are not dependent on a 
threshold level of damaged DNA.  
The work that has been done since 2006, has established that checkpoint 
adaptation occurs in osteosarcoma, lymphocytic leukemia and colon carcinoma 
cell types (Syljuåsen et al., 2006; Rezacova et al., 2011; Kubara et al., 2012).   
These cell lines underwent the three criteria for checkpoint adaptation: 1) a cell 
cycle arrest, 2) entry into mitosis, and 3) damaged DNA in mitotic cells, 
following exposure to radiation and CPT (Toczyski et al., 1997).  Checkpoint 
adaptation has also been suggested to occur in at least two other cell types 
including: hepatocellular carcinoma cells and normal human fibroblastic cells 
(Wang et al., 2008; Rezacova et al., 2011).  As well as prior to cell death by 
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mitotic catastrophe, checkpoint adaptation has also been suggested to occur in 
fibrosarcoma and adenocarcinoma cells (Clifford et al., 2003; Cahuzac et al., 
2010).  Although checkpoint adaptation may be occurring in these cell types 
following treatment with a DNA damaging agent, all three of the criteria for 
checkpoint adaptation were either not explored or insufficiently supported in these 
reports.  Therefore further work would need to be done to confirm that these cell 
lines undergo checkpoint adaptation.  Checkpoint adaptation also appears to be 
independent of the type of DNA damage including damage due to radiation, CPT, 
cisplatin, bleomycin, S23906 and etoposide (Syljuåsen et al., 2006; Wang et al., 
2008; Cahuzac et al., 2010; Rezacova et al., 2011; Kubara et al., 2012).  
Checkpoint adaptation also appears to be insensitive to a threshold of damaged 
DNA (Deckbar et al., 2007; Tkacz-Stachowska et al., 2011).  Prior to this thesis 
work, checkpoint adaptation had not been reported in brain cancer cells.   
   
1.6. Phosphorylation Status of Chk1 following Checkpoint Adaptation 
The precise mechanism by which cells undergo checkpoint adaptation is 
still unknown.  However, one component that has been proposed to be involved in 
establishing checkpoint adaptation is Chk1.   It is a component in the initiation of 
the DNA damage checkpoint and in establishing checkpoint recovery, and hence 
is a candidate for initiation of checkpoint adaptation
 
(Zhang et al., 2005).  Recent 
studies have explored the possibility of Chk1 as a mediator for checkpoint 
adaptation.  One such study was done by characterizing Chk1 inhibitors and 
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tracking the effect of Chk1 inhibition on cells that had been treated with a 
genotoxic agent (Ferry et al., 2011).  In this study, HT-29 cells were treated with 
CPT and followed by treatment with Chk1 inhibitors that were found to be active 
in checkpoint bypass.  The results of this study determined that a novel Chk1 
inhibitor (S27888) was effective in inducing human cancer cells to enter mitosis 
with damaged DNA and an activated Chk1.  This precocious cellular entry into 
mitosis with damaged DNA, following Chk1 inhibition, provides evidence that 
Chk1 inactivation is a component in checkpoint adaptation.      
There are two proposed mechanisms for the inactivation of Chk1 which 
therefore initiates checkpoint adaptation: 1) Chk1 degradation or 2) Chk1 
dephosphorylation (Syljuåsen et al., 2006; Zhang et al., 2009).  In either case, 
both mechanisms would disable the DNA damage checkpoint by removing the 
activity of Chk1, thereby resulting in activation of Cdk1 and resumption of the 
cell cycle.   
 
1.6.1. Chk1 Degradation Hypothesis 
Studies have demonstrated that at CPT concentrations higher than 500 
nM, human cancer cells will degrade Chk1 resulting in checkpoint termination 
(Zhang et al., 2005; Zhang et al., 2009).  Nevertheless, the plasma concentration 
of CPT analogues in patients is limited to 75 nM because of toxicity (Raymond et 
al., 2002b).  With this in consideration, the previous results indicating Chk1 
degradation as the cause of checkpoint abrogation in cells with damaged DNA, 
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are at concentrations over 6 times higher than what is found in a clinical setting.  
Further studies regarding the Chk1 degradation hypothesis were conducted and 
demonstrated Chk1 protein presence after treatment with clinically significant 
concentrations of genotoxic compounds
 
(Heffernan et al., 2002; Kurz et al., 2004; 
Cahuzac et al., 2010).  In 2012, a study was done that determined the role of 
proteolysis in checkpoint adaptation (Kubara et al., 2012).  This study 
demonstrated that in HT-29 cells, following 25 nM CPT treatment in conjunction 
with 300 nM MG132, a proteasome inhibitor, the process of checkpoint 
adaptation was not inhibited.  This indicated that Chk1 degradation was not the 
mechanism by which cells undergo checkpoint adaptation. 
 
1.6.2. Chk1 Dephosphorylation Hypothesis 
It has been shown that in yeast and Xenopus egg extracts, checkpoint 
adaptation is related to the loss of Chk1 phosphorylation, the release of claspin 
and therefore inactivation of Chk1 kinase (Pellicioli et al., 2001; Yoo et al., 
2004).  In humans, dephosphorylation at Ser317/345 of Chk1 was reported in 
U2OS cells that had undergone checkpoint adaptation (Syljuåsen et al., 2006).  
Together these results provided evidence that Chk1 dephosphorylation, not 
degradation, is a mechanism in checkpoint adaptation.  This hypothesis has since 
been confirmed in 2012 by Kubara et al. in HT-29 cells.  In this study, Chk1 was 
dephosphorylated at Ser345 following checkpoint adaptation, in comparison to 
interphase cells of the same population that remained phosphorylated at Ser345.  
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However these results could not distinguish whether dephosphorylation of Chk1 
occurred as the initiating event that drives cells into mitosis during the adaptation 
process, or alternatively, if dephosphorylation of Chk1 is a consequence of 
checkpoint adaptation.  If Chk1 dephosphorylation initiates checkpoint 
adaptation, then blocking Chk1 dephosphorylation should block checkpoint 
adaptation.  This could be tested by preventing Chk1 dephosphorylation, using 
phosphatase inhibitors.  The phosphatase that dephosphorylates Ser317/345 of 
Chk1 in cells has not yet been identified; however, there have been a number of 
phosphatases reported to dephosphorylate Chk1 at these amino acids. 
 
1.6.3. Protein Phosphatases 
Reversible protein phosphorylation is recognized to be an essential and 
widespread regulatory mechanism of a myriad of fundamental cellular processes, 
including the DNA damage response.  Reversible protein phosphorylations occur 
on about one-third of all proteins in human cells, and each protein 
phosphorylation (and dephosphorylation) affects the proteins activity and 
biological properties (Cohen, 2001).  For example, protein phosphorylation allows 
the regulation of enzymatic activities by mediating conformational changes, or by 
directly blocking access to enzyme catalytic sites, such as with Cdk1.  The level 
of protein phosphorylation is a reflection of a delicate balance between the 
phosphorylating activity of kinases and the dephosphorylating activity of 
phosphatases.  The specificity and reversible nature of these phosphorylations 
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would suggest there is a similar ratio of protein kinases to protein phosphatases in 
order to counteract their actions.   Surprisingly, the number of protein 
phosphatases encoded by the human genome is an order of magnitude lower than 
that of the number of kinases (Lander et al., 2001; Venter et al., 2001; Shi, 2009).  
This ratio is, in part, a result of distinct phosphatase isoforms that result in varied 
distribution and subcellular localizations.  However it is predominantly due to the 
ability of the phosphatase catalytic subunit to form heterodimeric or 
heterotrimeric holoenzymatic complexes with many protein regulatory subunits 
and targeting domains in a mutually exclusive manner, resulting in considerable 
structural diversity (Liu and Xu, 2011).  These changes in phosphatase 
confirmation result in distinct substrate specifications, restricted subcellular 
functions and diverse regulation.  This permits numerous cellular functions to be 
controlled independently by relatively few phosphatases (Barford et al., 1998).  
While the protein kinases responsible for cellular phosphorylations involved in 
the DNA damage response have been well documented, the role of protein 
phosphatases is less well known (Freeman and Monteiro, 2010).  Only recently 
has a better understanding of these phosphatases been developed.   
Phosphatases can be grouped into three distinct families based on substrate 
specificity, structure and catalytic function.  The largest class of protein 
phosphatases is the phosphoprotein phosphatase (PPP) family.  Next is the protein 
phosphatase Mg
2+ 
or Mn
2+ 
dependent (PPM) family, followed by the protein 
tyrosine phosphatase (PTP) family.  The PPP and PPM families dephosphorylate 
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phosphoserine and phosphothreonine residues (Ser/Thr) in a single reaction step 
using a metal-activated nucleophilic water molecule.  This makes them distinct 
from the PTP family, which dephosphorylates phosphotyrosine residues by use of 
a cysteinyl-phosphate enzyme intermediate (Barford et al., 1998).  For the 
purposes of this paper, only the phosphatases involved in the DNA damage 
response, the Ser/Thr phosphatases, will be discussed. 
Representative members of the PPP family include protein phosphatase 1 
(PP1), PP2A, PP2B (commonly known as calcineurin), PP4, PP5, PP6 and PP7 
(Barton et al., 1994; Cohen, 1997).  The PPM family includes protein 
phosphatases dependent on magnesium/manganese ions, such as PP2C, as well as 
the PP2C delta isoform Wip1 phosphatase (Shi, 2009).   
 
1.6.4. Candidate Phosphatases for the Dephosphorylation of Chk1 at Ser317/345 
In 2004, a study was done in Schizosaccharomyces pombe to identify 
proteins required for checkpoint release (den Elzen and O'Connell, 2004).  In this 
study, wild type, Dis2 overexpressing and Dis2 null cells were exposed to a 
variety of DNA damaging agents and then cell survival, repair rate and percent of 
cells passing through mitosis was monitored.  The DNA damaging agents used in 
this study included ionizing radiation (IR), ultraviolet radiation (UV), methyl 
methanesulfonate (MMS) and 4-nitroquinoline-N-oxide (4-NQO).  It was reported 
that dephosphorylation of Chk1 at Ser345 by Dis2, a PP1 homolog, allowed for 
mitotic entry upon completion of DNA repair in G2.  It was also demonstrated 
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that Dis2 null cells have a prolonged Chk1-dependent arrest and a compromised 
ability to downregulate Chk1 activity for checkpoint release.  Importantly, it was 
also reported that the overexpression of Dis2 caused precocious entry into mitosis 
in the presence of un- or partially repaired damaged DNA, resulting in an unequal 
division of DNA between daughter cells.  These results indicated that in S. pombe, 
overexpression of the PP1 homolog Dis2, and therefore enhanced Chk1 
dephosphorylation, caused aberrant mitosis.  Furthermore, they were able to show 
that Chk1 dephosphorylation by Dis2 could be abolished by inhibitor-2, which 
specifically inhibits PP1.   
In contrast, Petersen et al. (2006) studied the effects of induced DSB and 
PP2A inhibition on Chk1 phosphorylation at Ser344 (homologous to Ser345 of 
human Chk1) in Xenopus egg extracts.  As a source of DSBs, they used DNA 
digested with HaeIII, which generates blunt-ended double-stranded fragments that 
mimic DSBs in genomic DNA.  They analyzed the presence of Ser344-Chk1 
phosphorylation by SDS-PAGE and Western blotting.  It was reported that DSB-
induced Chk1 phosphorylation on Ser344 was strongly reversed by the addition of 
PP2A, suggesting that Chk1 is a substrate of PP2A.  They also found that 
treatment with the PP2A phosphatase inhibitor okadaic acid enhanced the DSB-
induced Chk1 phosphorylation at Ser344.  This finding suggested that PP2A was 
an antagonist of the Chk1 phosphorylation on Ser344.        
In human U20S cells, a 2005 study was done by Lu et al. to determine the 
effects of PPM1D (or Wip1, a PP2C delta isoform) on the dephosphorylation of 
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Ser345 of Chk1 and the effect it has on cell cycle checkpoints (Lu et al., 2005).  
By Western blotting and co-immunoprecipitation it was established that the 
phosphatase PPM1D, binds to Chk1.  By an in vitro phosphatase assay it was also 
reported that PPM1D dephosphorylates Ser345 of Chk1 and that this 
dephosphorylation lead to decreased Chk1 kinase activity.  It was also reported 
that PPM1D dephosphorylation correlated with reduced G2/M checkpoint activity 
in response to radiation induced damaged DNA.  At varying times following 
irradiation, U2OS cells were fixed and analyzed for DNA content and mitosis by 
flow cytometry and phospho-histone H3 content.  They reported that the reduction 
of PPM1D by PPM1D siRNA produced an 85% reduction in M-phase cells by 8 h 
which remained reduced up to 48 h.  Based on these results, Lu and colleagues 
suggested that the function of PPM1D may be to reverse the Chk1 induced DNA 
damage checkpoint following completion of DNA repair.  There was no 
investigation into the level of DNA damage present in the cells that entered into 
mitosis following irradiation.  And in the absence of PPM1D, the level of cells in 
mitosis was 85% reduced for up to 48 h only, therefore PPM1D inhibition did not 
completely prevent cells from entering into mitosis following irradiation.           
Conversely, in 2006 Leung-Pineda et al. had several observations 
regarding Chk1 dephosphorylation in human cells.  Human HeLa cells were 
treated with the genotoxic agent, hydroxyurea (HU), and then incubated with 
okadaic acid or fostriecin, both PP2A inhibitors.  Using SDS-PAGE and Western 
blotting they demonstrated that treatment of cells with HU, followed by exposure 
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to either fostriecin or okadaic acid, blocked Chk1 dephosphorylation at 
Ser317/345.  On the contrary, when cells were incubated with I-2, a PP1 inhibitor, 
Chk1 dephosphorylation was not blocked in cell extracts.  Secondly Ser317/345-
phosphorylated Chk1 accumulated in cells with PP2A levels reduced by siRNA 
treatment, and PP2A was able to directly dephosphorylate Chk1 on Ser317/345 in 
vitro.  Collectively, these results argued that PP2A regulates Chk1 in vivo.  
However, Leung-Pineda et al. also speculated that PP2A might not be the sole 
phosphatase that dephosphorylates Chk1 and that PP4, PP6 and Wip1 may also 
have roles in the dephosphorylation of Chk1 at Ser317/345.  This study provided 
supporting evidence that PP2A may be the protein phosphatase that 
dephosphorylates Ser317/345 of Chk1.  However they did not investigate 1) any 
changes in cell cycle arrest or abrogation, 2) the number of cells that entered into 
mitosis following HU treatment or 3) the level of DNA damage present in cells. 
Therefore it was not clear as to whether PP2A inhibition was able to prevent cells 
from entering into mitosis with damaged DNA.    
In 2010 Landsverk et al. demonstrated PNUTS (protein phosphatase 1 
nuclear-targeting subunit), one of the most abundant nuclear-targeting subunits of 
PP1, played a distinct role in the DNA damage response by facilitating the 
dephosphorylation of Chk1 following DNA damage.  In this study, the human 
cervical cancer cell line HeLa was exposed to radiation at a dose rate of 4.3 
Gy/min and the phosphorylation of Ser317 and Ser345 of Chk1 was determined 
by Western blotting.  They reported Chk1 remained phosphorylated at Ser317/345 
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for up to 24 h, following PNUTS depletion.  They were also able to demonstrate 
that PNUTS overexpression inhibited a G2 arrest.  These results indicated that the 
inhibition of PP1 activity was able to prevent the dephosphorylation of 
Ser317/345 of Chk1 following exposure to ionizing radiation for up to 24 h.  
However this study did not discuss if inhibition of PNUTS was able to prevent 
cells from entering into mitosis with damaged DNA.   
Taken together, three protein phosphatases, PP1, PP2A, and PP2C 
(PPM1D or Wip1), have been proposed as candidates for Chk1 dephosphorylation 
at Ser317/345 in response to checkpoint activation.  In order to determine if Chk1 
dephosphorylation is responsible for priming checkpoint adaptation, inhibition of 
these candidate phosphatases, to prevent the dephosphorylation of Ser345-Chk1, 
will be essential in order to determine the effect of this inhibition on checkpoint 
adaptation.    
 
1.6.5. Protein Phosphatase Inhibitors 
The activity of protein phosphatases can be impaired by a number of 
inhibitors that have been reported to produce a wide range of physiological 
effects, such as tumor suppression or promotion (Cohen et al., 1990).  Several of 
these phosphatase inhibitors were first identified as naturally occurring human 
toxins, and proved useful in identifying the physiological responses and processes 
regulated by serine/threonine protein phosphatases.  The degree of the effects 
these inhibitors have is often determined by 1) the exposure duration and 
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concentration of the inhibitor; 2) the cell type exposed to the inhibitor and 3) the 
cell permeability of the inhibitor (Mackintosh and Mackintosh, 1994).  One 
inhibitor can differentially inhibit several different protein phosphatases 
depending on inhibitor concentration (Pereira et al., 2011).  In determining 
phosphatase inhibitors for the three candidate phosphatases for dephosphorylating 
Ser345 of Chk1 (PP1, PP2A, PP2C) the inhibitors for PP1 and PP2A are 
separated into three categories: 1) those inhibiting PP1 and PP2A with equal 
selectivity including microcystin-LR and calyculin A; 2) those inhibiting PP1 
more potently than PP2A, including tautomycin and 3) those inhibiting PP2A 
more potently than PP1, including okadaic acid, cantharidin, nodularins and 
fostriecin.  Phosphatase PP2C has one primary inhibitor called sanguinarine 
(Aburai et al., 2010).  Phosphatase inhibitor specificity and efficiency, including 
each phosphatase IC50 as well as intracellular phosphatase inhibition 
concentrations is summarized in Table 1.  Intracellular phosphatase inhibition 
concentrations have been included for an accurate determination of in vivo 
phosphatase inhibition efficiency. 
The cell cycle is regulated through an intricate network of reversible 
phosphorylations by protein kinases and phosphatases.  As such, inhibition of key 
processes in this regulation system, including both phosphorylation and 
dephosphorylation, can result in abnormalities in cell cycle functioning, such as 
checkpoint abrogation.  Such abnormalities have been reported following cellular 
treatment with various phosphatase inhibitors.  In particular, cantharidin, okadaic  
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Table 1 Serine/Threonine specific protein phosphatase inhibitors and their respective IC50 
values and intracellular phosphatase inhibition concentrations 
Phosphatase 
Inhibitor 
PP1 IC50 
(nM) 
 
PP2A IC50 
(nM) 
PP2C IC50 
(μM) 
Intracellular Inhibition and Cell 
line 
Okadaic Acid 1.24-60 
(Pereira et al., 
2011) 
 
0.1-1 
(Pereira et al., 
2011) 
 
- PP2A- 0.25 μM 
E18 rat primary 
cortical neuron 
(Rudrabhatla et al., 
2009) 
PP2A- 500 nM 
Human lung 
fibroblasts 
MRC-5 cell line 
(Cairns et al., 1994) 
Cantharidin 
 
500-1700 
(Pereira et al., 
2011) 
 
40-160 
(Pereira et al., 
2011) 
 
- PP2A- 20 μM 
Human lung 
fibroblasts 
MRC-5 cell line 
(Cairns et al., 1994) 
PP2A- 0.2 μM 
Human 
endothelial cells 
(Loktionova & 
Kabakov, 1998) 
Tautomycin 
 
0.19-0.67 
(Pereira et al., 
2011) 
0.94-10 
(Pereira et al., 
2011) 
- PP1- 10 μM 
Human breast cancer cell 
MCF7 cell line 
(Favre et al., 1997) 
Microcystin-
LR 
0.1-6 
(Toivola and 
Eriksson, 
1999) 
0.04-2 
(Toivola and 
Eriksson, 
1999) 
- PP2A- 15 μM 
E18 Rat primary cortical neuron 
(Rudrabhatla et al., 2009) 
Calyculin A 0.3-2.5 
(Pereira et al., 
2011) 
0.5-7.3 
(Pereira et al., 
2011) 
- Both PP1 and 
PP2A- 100 nM 
Human kidney 
cells 
HEK293 cell line  
(Spurney, 2001) 
Both PP1 and 
PP2A- 10 nM 
Human breast 
cancer cell 
MCF7 cell line 
(Favre et al., 1997) 
Nodularins 0.3-1.8 
(Pereira et al., 
2011) 
0.03-0.2 
(Pereira et al., 
2011) 
- Phosphatase not specified- 2 μM 
Rat hepatocytes 
(Eriksson et al., 1990) 
Fostriecin 4000-
131,000 
(Pereira et al., 
2011) 
1.5-40 
(Pereira et al., 
2011)  
- PP2A- 1 μM 
E18 Rat primary cortical neuron 
 
Sodium 
Fluoride 
 
2.1 mM 
(Stubbs et al., 
2001) 
 
40 mM  
(Fathi et al., 
2002) 
- PP2A- 10 mM 
Human breast cancer 
PMC42 cell line (cell extract) 
(Li et al., 1997) 
 
Sanguinarine 
- - 2.38-2.62 μM 
(Aburai et al., 
2010) 
PP2C- 0.37 μM 
Promyelocytic Human leukemia  
HL60 cell line 
(Aburai et al., 2010) 
Note. IC50 determined by enzyme assay (in vitro) 
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acid and fostriecin have been shown to cause cells to enter prematurely into 
mitosis, inducing cell death (Cheng et al., 1998; Sakoff et al., 2004; Bonness et 
al., 2006).  In 1998 Cheng et al. treated Chinese hamster ovary cells (CHO) with 
the protein phosphatase inhibitors fostriecin, okadaic acid and cantharidin, all 
which resulted in a G2/M phase “mitotic block”.  CHO cell homogenates were 
treated with either: 10 µM fostriecin, 30 µM okadaic acid or 5 µM cantharidin, 
concentrations at which the protein phosphatase PP2A was inhibited, as 
determined by phosphatase activity assay.  Following treatment, flow cytometry 
results indicated a dose dependent increase in 4N DNA content, suggesting that 
cell cycle arrest was occurring after DNA replication but prior to completion of 
anaphase.  Light microscopy revealed that following phosphatase inhibitor 
treatment, the cells became rounded in appearance and were easily detached from 
the flask, a morphologic characteristic of cells in mitosis.  Trypan blue exclusion 
revealed rounded cells were viable, and cells treated 18 h or less could recover 
when plated in fresh media without phosphatase inhibitors.  However when 
treated for more than 24 h, cells did not recover and died by apoptosis.  They were 
also able to determine that the “mitotic block” was associated with aberrant 
spindle apparatus formation and abnormal chromosome replication.  This study 
was not in the scope of checkpoint adaptation as they did not treat cells with a 
DNA damaging agent.      
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1.7. Checkpoint Adaptation in Brain Cancer 
Prior to this thesis work there were no published demonstrations of 
checkpoint adaptation in brain cancer cells.  Therefore the demonstration of 
checkpoint adaptation in brain cancer cells would be a valuable contribution to the 
still limited knowledge we have on checkpoint adaptation.    
 
1.7.1. Brain Cancer 
Brain cancer is typically classified by cell origin and frequently on a 
grading system, based on aggressiveness and rate of growth.  Clinically, the grade 
system ranges from Grade I (least malignant) to Grade IV (most malignant).  A 
glioma is a type of tumor that starts in the brain or spine arising from glial cells 
(Kleihues and Sobin, 2000).  An astrocytoma is a glioma that develops from star-
shaped glial cells, called astrocytes, which support nerve cells.  Astrocytomas are 
classified based on the grading system, with the glioblastoma also referred to as 
glioblastoma multiforme (GBM) being the most common grade IV astrocytoma in 
humans. 
GBM is the most common primary malignant glioma in adults comprising 
about one-fifth of all adult primary brain tumours and is considered to be one of 
the deadliest human cancers (Alves et al., 2011).  GBMs are characterized by a 
high proliferative rate, aggressive invasiveness and insensitivity to radio or 
chemotherapeutic treatments.  They are also characterized with a high mortality 
rate and a short patient survival period of less than one year.   
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1.7.2. Standard Treatment for Glioblastoma  
Treatment of GBM is difficult and has a poor success rate due to several 
complicating factors including tumor cell resistance to conventional therapies and 
limited chemical accessibility to the brain by the blood brain barrier (BBB) 
(Lawson et al., 2007).  The brain is also highly susceptible to damage and has 
limited repair capabilities.  Standard treatment for GBM generally consists of 
surgical resection for the majority of the tumor mass (when possible) followed by 
radiation therapy, chemotherapy or a combination of both (Kanu et al., 2009; 
Minniti et al., 2009).  The goal of surgical resection is to remove as much of the 
tumour as possible.  Whereas surgical removal is a mainstay of therapy, radiation 
and chemotherapy are often needed to address the microscopic tumour cells that 
may remain from the surgery or may have spread through nearby tissues.   
A variety of chemotherapeutic drugs have been tested and used in 
chemotherapy treatment for GBM.  Among the list of chemicals used in the 
treatment of primary brain tumours is CPT, as well as a number of CPT analogs 
including topotecan and irinotecan (Friedman et al., 1999; Raymond et al., 2002a; 
Raymond et al., 2002b; Feun and Savaraj, 2008).  Although there have been 
several advances in primary brain tumour treatment, the efficacy of 
chemotherapeutic treatment is limited, given that few therapeutic agents have 
proven to be effective in treating brain tumours.  This lack of effective treatment 
remains a significant challenge for clinicians and necessitates the development of 
new strategies for brain cancer therapy.    
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1.7.3. Significance for Investigating Checkpoint Adaptation in Brain Cancer 
Although there has been a vast amount of research done exploring 
glioblastomas and even glioblastoma cells treated with DNA damaging agents, 
there were no published reports of checkpoint adaptation in cells from a primary 
brain tumor.  Much of the work done with glioblastomas and DNA damaging 
agents has been in the context of exploring the initiation and control of the DNA 
damage checkpoint following exposure to radiation or chemotherapeutic agents 
(Fernet et al., 2008; Sorensen et al., 2010; Cheng et al., 2011).   
There has been a report on the possibility of mitotic catastrophe occurring 
in glioblastoma cells exposed to a genotoxic agent.  In 2001, a study was done 
exploring the anti-tumour potential of the DNA methylating agent temozolomide 
(TMZ) (Hirose et al., 2001).  During this study a p53-deficient glioblastoma cell 
line, U87MG-E6, was treated with 100 µM TMZ, resulting in a G2/M phase arrest 
that was thereafter bypassed, ending in cell death.  This result was reported to be 
mitotic catastrophe.  However there was no investigation into the level of DNA 
damage present in the cells that entered into aberrant mitosis, therefore it cannot 
be confirmed whether these cells had undergone checkpoint adaptation.   
M059K is one glioblastoma cell line commonly used to study the effects 
of genotoxic agents and the DNA damage checkpoint.  The M059K cell line is a 
p53-deficient human fibroblastic glial cell line cultured from the glioblastoma of 
33 year old male (Allalunis-Turner et al., 1993; Lees-Miller et al., 1995).  This 
cell line is unique and a prominent candidate for research in DNA damaging 
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agents and the DNA damage checkpoint because M059K has a sister cell line 
called the M059J cell line.  The M059J cell line was isolated from the same 
tumour; however, it is the only human cell line known to lack DNA-PK catalytic 
subunit (DNA-PKcs).  Therefore it fails to produce the DNA-PK protein, a 
protein important in the DNA damage response.  The inability of the M059J cell 
line to produce the DNA-PK protein, results in a decreased ability of this cell line 
to repair DNA DSBs and increased sensitivity to DNA damaging agents.  This 
factor has resulted in the M059K and M059J cell lines becoming frequently used 
in cancer cell research studying the cellular response to genotoxic agents, such as 
radiation or chemotherapeutic agents.  However, the general focus of research on 
the M059K cell line, when treated with DNA damaging agents, has often been 
resolved around progression through the cell cycle, as well as initiation and 
control of the G2/M checkpoint and DNA damage repair (Virsik-Kopp et al., 
2003; Block et al., 2004; Liu et al., 2008; Dejmek et al., 2009).  Prior to this 
thesis, there had been no demonstration of checkpoint adaptation in the M059K 
cell line or in any brain cancer cell line. 
In 2003 it was reported that following exposure to low and high LET 
(linear energy transfer) radiation there was an increase in radiation induced-giant 
cells as well as cells displaying ‘mitotic catastrophe’, in the M059J cell line at 144 
h post-irradiation (Holgersson et al., 2003).  The detection of giant-cells and 
‘mitotic catastrophe’ was based on morphological changes and the number of 
cells that displayed these two categories was scored out of 500 cells total.  Taken 
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together the number of cells displaying either or both of these two categories 
increased from 0.7% at a background level to 4% for low (4 Gy) and 10% for high 
(1 and 4 Gy) LET radiation exposure.  However, radiation-induced giant cells and 
‘mitotic catastrophe’ was not detected in the M059K cell line.  In 2005 
Holgersson et al. reported that following exposure to high LET there was a 
substantial increase in the number of M059J and M059K cells in the G2/M phase 
arrest at 48 h post exposure.  They also reported that following treatment with 10 
or 40 µg/mL of the radiomimetic drug bleomycin, a large portion of both M059J 
and M059K cells remained in a G2/M phase arrest as detected by flow cytometry.  
They further reported that this distinct cell cycle block was released in both cell 
types but was dependent on the amount of LET exposure and the presence of 
DNA-PK.  However, neither of these reports investigated the level of DNA 
damage present in cells and ‘mitotic catastrophe’ was determined based on 
morphological changes alone.  Therefore it cannot be confirmed whether these 
cells had undergone checkpoint adaptation.     
Investigation of checkpoint adaptation in cells from a glioblastoma would 
be a valuable contribution to the current body of knowledge regarding checkpoint 
adaptation for a number of reasons.  First, the glioblastoma is one of the most 
common types of primary brain cancer, and the current standard of care includes 
genotoxic therapies with chemicals including CPT and analogs.  Also, there is a 
need for improved brain cancer treatment.  This is a result of the difficulty in 
successful treatment of brain tumors due to the relatively poor response to 
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standard genotoxic treatments, as well as the poor prognosis for survival 
following diagnosis.  The demonstration of checkpoint adaptation in a 
glioblastoma would further broaden the base of our still limited core knowledge 
on this poorly understood process and strengthen the argument that checkpoint 
adaptation occurs universally in cancer cells following genotoxic treatment. 
 
1.8. Overview of Thesis 
Checkpoint adaptation is a poorly understood process defined by a cell 
entering into mitosis, after an extended G2/M checkpoint arrest, despite the 
presence of damaged DNA.  Checkpoint adaptation was first demonstrated in 
human cancer cells in 2006, following treatment with radiation, a commonly used 
form of cancer treatment (Syljuåsen et al., 2006).  Checkpoint adaptation occurs 
in three cancer cell lines including osteosarcoma, lymphocytic leukemia and colon 
carcinoma, following genotoxic treatment with radiation or CPT (Syljuåsen et al., 
2006; Rezacova et al., 2011; Kubara et al., 2012).  Checkpoint adaptation has also 
been suggested to occur in other cancer cell lines (Wang et al., 2008; Cahuzac et 
al., 2010; Rezacova et al., 2011).  It was shown recently that the majority of cells 
that enter into mitosis with damaged DNA die, however approximately 2% of 
them survive and continue to divide and may have a highly rearranged genome 
(Kubara et al., 2012).  The outcome for the cells that survive checkpoint 
adaptation is unknown, however further genome instability has been implicated, 
which may provide insight into cancer developments such as secondary tumours 
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and cancer cell resistance to genotoxic treatments (Nakada et al., 2006; Nitiss, 
2009).   
Prior to my thesis work, a demonstration of checkpoint adaptation in a 
glioblastoma cell line had not yet been done.  Investigation into whether 
checkpoint adaptation occurs in cells from a glioblastoma would provide further 
evidence that this is a universal process in cells exposed to genotoxic agents.  
There have also been implications regarding Chk1 inactivation by 
dephosphorylation, as the potential mechanism or inciting event that allows for 
checkpoint adaptation to occur.  Exploring the potential effects of inhibiting Chk1 
dephosphorylation using phosphatase inhibitors, and what effect this has on 
checkpoint adaptation may provide a deeper insight into the molecular mechanism 
of checkpoint adaptation.  There remains much to be discovered and understood 
regarding the biological process and significance of checkpoint adaptation.  In the 
future we may find that either inhibiting or exploiting checkpoint adaptation may 
improve and/or change our current approaches to cancer treatments. 
 
1.8.1. Research Objectives 
The purpose of this research project was to determine if checkpoint 
adaptation occurs in the brain cancer cell line M059K when treated with the 
genotoxic anticancer agent CPT.  It was also focused on determining how 
inhibition of Chk1 dephosphorylation at Ser345, using phosphatase inhibitors, 
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would affect the process of checkpoint adaptation.  Several smaller objectives 
were addressed to achieve this purpose: 
 
1. Introduce and characterize the brain cancer cell line M059K in the 
laboratory. 
 
2. Determine a cytotoxic concentration of CPT for the brain cancer cell 
line M059K (Chapter 2). 
 
3. Assess if M059K cells enter into an extended DNA damage induced 
G2 phase cell cycle arrest following treatment with CPT (Chapter 2).  
 
4. Determine if cells overcome this G2 phase arrest and enter into mitosis 
with damaged DNA (Chapter 2). 
 
5. Find the cytotoxicity of several candidate phosphatase inhibitors for 
the HT-29 cell line to determine treatment concentration (Chapter 3). 
 
6. Determine if there is an effect on the number of cells that undergo 
checkpoint adaptation following treatment with candidate phosphatase 
inhibitors (Chapter 3).      
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Chapter 2 
2.  Checkpoint Adaptation in the M059K Cell Line 
 
2.1. Introduction 
In 2006, checkpoint adaptation was demonstrated in human osteosarcoma 
cells following treatment with radiation (Syljuåsen et al., 2006).  This was the 
first time checkpoint adaptation was observed in human cells.  A study published 
by the Golsteyn laboratory reported that checkpoint adaptation also occurs in 
human colon cancer cells treated with CPT or in cells treated with novel DNA 
alkyating agents (Kubara et al., 2012).  For this research project, human brain 
cancer cells were tested to determine if they undergo checkpoint adaptation 
following treatment with CPT.  Knowledge of this is important because gliomas 
are difficult to treat, and typically receive forms of treatment that have been 
shown to cause checkpoint adaptation in other cell lines, including CPT and 
radiation.  To identify checkpoint adaptation in brain cancer cells, I followed the 
criteria established by Toczyski and colleagues (1997).  The process of 
checkpoint adaptation is defined by three features in cells with damaged DNA: 1) 
cell cycle arrest, 2) entry into mitosis, and 3) damaged DNA in mitotic cells.     
Damaged DNA in cells results in the activation of the DNA damage 
checkpoint (Kastan and Bartek, 2004; Bartek and Lukas, 2007).  This checkpoint 
activation results in phosphorylation of the protein histone H2AX, which is then 
known as γ-H2AX (Rogakou et al., 1998).  Gamma-H2AX is a standard marker 
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for the presence of damaged DNA (Bonner et al., 2008).  Checkpoint activation 
also results in the phosphorylation of protein substrates, including Chk1 at 
Ser317/345, causing a G2 phase cell cycle arrest.  In cells that undergo checkpoint 
adaptation, the G2 cell cycle arrest is abrogated and cells enter into mitosis 
despite having damaged DNA (Toczyski et al., 1997; Syljuåsen et al., 2006; 
Kubara et al., 2012).  Entry into mitosis is characterized by morphological 
changes at cellular and nuclear levels, such as cell rounding and chromatin 
condensation (Harris, 1973).  It is also characterized by biochemical changes such 
as phosphorylation of histone H3, which is a common marker of cells in mitosis 
(Hendzel et al., 1997).   
Most of the cells that undergo checkpoint adaptation die; however, a small 
number of them survive (Kubara et al., 2012).  It is not known whether the cells 
that survive checkpoint adaptation have a changed genome as one might expect if 
cells are dividing with damaged DNA.  These experiments provided the 
opportunity to examine the outcome of cells that survived checkpoint adaptation 
for signs of genomic instability.  
To investigate whether checkpoint adaptation occurs in brain cancer cells, 
and to determine if there is evidence of genomic change in surviving cells, the 
human brain cancer cell line M059K was studied.  This cell line is from a human 
fibroblastic glioma and was chosen because it is frequently used in research on the 
DNA damage response, has a mutant p53 tumour suppressor status and is 
sensitive to CPT treatment (Virsik-Kopp et al., 2003; Holgersson et al., 2005; Li 
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and Stern, 2005; Mi et al., 2009).  This thesis reports that following treatment 
with cytotoxic and pharmacologically relevant concentrations of CPT, that 
M059K cells enter a G2 checkpoint arrest.  The arrested cells abrogate the 
checkpoint and enter into mitosis with damaged DNA.  This thesis also reports 
that after treatment with CPT, M059K cells acquire micronuclei, a marker 
consistent with cells that have genomic change (Hovhannisyan et al., 2009).  
These findings suggest M059K cells undergo checkpoint adaptation and surviving 
cells have a rearranged genome.   
                   
2.2. Materials and Methods 
 
2.2.1. Cell Culture 
Human M059K cells (American Type Culture Collection) were 
maintained in Dulbecco’s Modified Eagle medium- DMEM ⁄ F-12 (Invitrogen) 
supplemented with 10% decomplemented fetal calf serum (PAA Laboratories, 
Etobicoke, Ontario), 2 mM non-essential amino acids (Invitrogen) and 15 mM 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.4.  Cells were 
grown at 37°C in 5 % CO2 and media were changed every second or third day.  
M059K cells were plated at 150,000 cells/25 cm
2
 flask cultivated for 48 h prior to 
treatment.  The compound CPT (Sigma) was dissolved in dimethyl sulfoxide 
(DMSO) to a concentration of 10 mM and stored at -20C until further use. 
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2.2.2. Cytotoxicity Assay 
Cytotoxicity of CPT on M059K cells was measured by the microculture 
tetrazolium assay (MTT; (3-(4,5)- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) (Mosmann, 1983). M059K cells were plated at 4,000 cells/31 mm
2
 well 
and cultivated for 48 h prior to treatment.  Results were expressed as IC50, the 
compound concentrations that reduced by 50% the absorbance at 590 nm, 
compared to DMSO treated cells.  All measurements were done in triplicate at 48, 
72 and 96 h.   
 
2.2.3. Flow Cytometry 
Cells were plated at 150,000 cells/25 cm
2
 flask cultivated for 48 h prior to 
treatment.  At desired times after treatment, total cell cultures were trypsinized, 
washed in phosphatase-buffered saline (PBS) and fixed in 90% ethanol (-20°C) 
for at least 24 h.  Fixed cell suspensions were blocked for 1 h with labelling buffer 
(PBS, 5% serum, 1% bovine serum albumin (BSA), 0.1% sodium azide). Cells 
were incubated with anti-serine 10 phosphorylated histone H3 antibody for 2 h, 
then incubated with wash buffer twice for 20 min (No. 06 -570, Millipore, 1:100 
dilution) and 30 min incubation with FITC-conjugated secondary antibody (No. 
SC-2012, Santa Cruz, 1:100 dilution) in labelling buffer.  Cells were washed with 
wash buffer (PBS, 1% BSA, 0.1% sodium azide) and separated by centrifugation 
(Kubara et al., 2012).  For analysis, samples were incubated for 20 min in wash 
buffer with 0.02 mg/mL propidium iodide (Invitrogen) and 0.2 mg/mL RNAse A 
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(Sigma), and analysed with a FACS Canto II™ flow cytometer (BD Biosciences) 
using BD FACSDiva™ software. Gating was set using control samples without 
primary antibody. Experiments were repeated at least twice.   
 
2.2.4. Extract Preparation  
Cells were suspended in extraction buffer (50 mM HEPES, 50 mM NaF, 
10 mM EGTA (ethyleneglycol-bis (beta-aminoethylether)- N,N'-tetraacetic acid), 
50 mM β-glycerophosphate, 1 mM ATP, 1 mM DTT (dithiothreitol), 1% Triton 
X-100, 10 μg/mL RNAse A, 0.4 U/mL DNAse I, with Roche protease inhibitors 
cocktail) at a concentration of 20,000 cells per uL, on ice for 30 min.  After five 
passages through a 26 g needle at 4°C, the suspension was centrifuged at 12,000 x 
g for 10 min at 4°C (Kubara et al., 2012).  Extracts were further used for 
electrophoresis after being boiled for 3 min in presence of 2x SDS sample buffer 
(20% Glycerol, 10% DTT, 6% SDS, 500mM Tris, pH 6.84).   
 
2.2.5. Electrophoresis and Western Blotting 
Cell extract samples were run on polyacrylamide gels.  Protein loading 
was confirmed by Coomassie blue staining of gels run in parallel or by anti-actin 
Western blotting.  Molecular weight markers (Precision Plus) were from BioRad.  
Proteins were wet transferred to nitrocellulose for 16 hours at 25 volts.  
Subsequently, the membrane was blocked with either 5% low fat milk in Tris 
buffered saline TBS-0.1% Tween-20 (TBST) or 5% BSA in TBS-0.1% Tween-20 
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(TBS-T), and incubated overnight with the primary antibody anti-Chk1 (SC-8408, 
Santa Cruz, 1:200), anti-phospho ser345 Chk1 (2341S, Cell Signalling, 1:1000), 
or anti-actin (SC-58673, Santa Cruz, 1:200).  Following washes, the membrane 
was incubated with alkaline phosphatase-coupled anti-mouse IgG or anti-rabbit 
IgG for alkaline phosphatase (AP) detection (BioRad) (Kubara et al., 2012). 
 
2.2.6. Light Microscopy  
Cell images were taken with an Infinity 1.5 camera powered by Infinity 
Capture (Lumenera Corporation) software.  Live cells were detected by vital dye 
exclusion method using Amresco® Trypan Blue 0.4% solution (VWR, Canada).    
 
2.2.7. Immunofluorescence Microscopy 
Cells were plated on glass coverslips at 25,000 cells/9.6cm
2
 well and 
cultivated for 48 h prior to treatment, then fixed in 3% formaldehyde for 20 min at 
room temperature.  Cells were permeabilized for 5 min in 0.2% Triton X-100 then 
incubated with either anti-histone gamma H2AX (No. 05-636, Millipore), or anti-
serine 10 phosphorylated histone H3 (No. 06-570, Millipore), or anti-Lamin A/C 
(No. SC-6215, Santa Cruz Biotechnology) for 2 h at room temperature (Cahuzac 
et al., 2010).  Secondary antibodies: Texas Red anti-rabbit (Jackson/Beckman 
Boulter) for anti-histone H3, Alexa488 anti-mouse (Molecular Probes/Invitrogen) 
for anti-histone gamma H2AX, and Alexa488 anti-goat (Molecular 
Probes/Invitrogen) for anti-Lamin A/C were added for 2 h.  Nuclei were stained 
 50 
 
with 300 nM 4',6-diamidino-2-phenylindole (DAPI) in PBS for 15 min prior to 
mounting (Kubara et al., 2012).  Cells were observed on a Zeiss microscope 
operated by Axiovision 3.1 software.  Images were collected by Zeiss MR camera 
within the linear dynamic range.  Images were prepared with Adobe Photoshop 
CS3 10.0 software.  Cells positive for phospho-histone H3, gamma-H2AX or 
Lamin A/C were counted.  Experiments were repeated at least twice.      
                     
2.2.8. Statistics 
Graphing was done using Microsoft Excel 2007.  Data was collected and 
plotted as means ± standard deviations of the mean.  GraphPad Prism 5 software 
was used to generate dose response curves and estimate IC50.        
 
2.3. Results 
 
2.3.1. Cytotoxic Concentrations of CPT in the M059K Cell Line 
To assess whether M059K cells undergo checkpoint adaptation, a 
concentration of CPT with which to treat the cells was determined.  M059K cells 
were treated with increasing concentrations of CPT and their viability was 
measured at 48, 72 and 96 h by the MTT assay (Mosmann, 1983).  The IC50 for 
CPT treated cells was 19.95 nM at 48 h, 5.67 nM at 72 h and 2.78 nM at 96 h post 
treatment (Figure 3).  These values were within the range of CPT and CPT 
derivatives found in human patient serum following cancer treatment (Rivory et  
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al., 1997; Raymond et al., 2002b).  Therefore a concentration of 25 nM was 
chosen for subsequent experiments because it is similar to human patient values, 
validating our pharmacological approach.  Data from the MTT assay also 
revealed that at 48 h cells treated with 7.5 nM, and to a lesser extent 25 nM, were 
alive but would die by 96 h.  The concentration of 7.5 nM provided a larger 
window at which the cells were viable prior to cell death.  For this reason, a 
concentration of 7.5 nM CPT was also used in subsequent experiments.  These 
data indicate that 25 nM and 7.5 nM are cytotoxic and pharmacologically relevant 
concentrations of CPT for the M059K cell line.        
 
2.3.2. Cells Treated with CPT Become Arrested in the G2 Phase of the Cell Cycle 
Having established that M059K cells are sensitive to pharmacologically 
relevant concentrations of CPT, next it was addressed whether they undergo 
checkpoint adaptation.  First cells were examined by flow cytometry to measure 
DNA content, in order to detect a cell cycle arrest.  Cells have one copy of DNA 
prior to DNA replication in S phase, denoted 2N DNA.  Whereas cells that have 
undergone DNA replication contain 2 copies of DNA, denoted 4N DNA, until the 
two copies are separated in anaphase of mitosis at which point they have 2N DNA 
again.  M059K cells were treated with 25 nM CPT for 24 h or 48 h then analyzed 
for DNA content by flow cytometry.  At 24 h following treatment, cells had 
accumulated predominantly in S phase, as indicated by the accumulation of 2N 
DNA.  By 48 h the cells accumulated in the G2 phase of the cell cycle, as 
 53 
 
indicated by the accumulation of 4N DNA (Figure 4).  The flow cytometry data 
indicated M059K cells were alive and arrested in the G2 phase of the cell cycle 
following treatment with a pharmacologically relevant and cytotoxic 
concentration of CPT.   
 
2.3.3. Cell Treated with CPT Activate the DNA Damage Checkpoint 
Typically cells that are arrested in the G2 phase of the cell cycle have a 
phosphorylated Chk1 at Ser317/345.  Phosphorylation of Chk1 at Ser317/345 is a 
result of the activation of the DNA damage checkpoint.  Therefore untreated and 
7.5 nM CPT treated M059K cells were examined for the presence of Chk1 and 
phosphorylated Ser345-Chk1.  These results were compared to untreated and 
treated HT-29 cells as a control.  All cell extracts, both untreated and CPT treated, 
contained Chk1, and as predicted, CPT treated cells contained phosphorylated 
Ser345-Chk1 (Figure 5).  These findings confirmed that M059K cells are 
sensitive to CPT at a pharmacologically relevant concentration.  They also 
indicated that following treatment with CPT, M059K cells arrest in the cell cycle 
and contain activated Chk1.   
 
2.3.4. Cells Treated with CPT Acquire a Rounded Shape 
The next step was to determine if the cells that had become arrested in the 
G2 phase of the cell cycle would abrogate the cell cycle checkpoint and enter into  
 
 54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 55 
 
 
 
 
 
 
 56 
 
mitosis, the second defining feature of cells that have undergone checkpoint 
adaptation.  M059K cells were treated with 25 nM CPT and observed by light  
microscopy for morphological changes, such as cell rounding.  Following 24 h 
treatment, the majority of the cells were flat and strongly adherent to the flask; 
however at 48 h following treatment, cells became rounded (Figure 6).  These 
rounded cells were weakly adherent and could be collected by a mechanical 
shake-off, leaving behind only flattened adherent cells.  The remaining adherent 
culture was recultivated and observed.  After 2 h more rounded cells appeared 
indicating that the flattened cells were the source of rounded cells and that this 
was a continuous process.    
 
2.3.5. Cells Enter into Mitosis following the G2 Phase Checkpoint Arrest  
The next step was to confirm that the rounded cells were in mitosis.  
Chromosomes in mitotic cells contain phospho-ser10 histone H3 therefore cells 
were examined for phospho-ser10 histone H3 by flow cytometry.  Cells were 
either untreated, treated with 25 nM CPT for various times or treated with 
nocodazole for 24 h then stained for phospho-ser10 histone H3 and analyzed by 
flow cytometry.  Nocodazole was used as a positive control as it interferes with 
microtubule polymerization resulting in cells that are blocked in mitosis.  The 
number of cells positive for phospho-ser10 histone H3 in the untreated fraction 
was 1.5% and 7.0% in the nocodazole treated fraction.  At 24 h CPT treatment the  
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number of cells positive for phospho-ser10 histone H3 was 0.8%, which increased 
to 3.4% at 48 h, 4.9% at 72 h and 4.6% at 96 h (Figure 7).  The results of this 
experiment demonstrated that in comparison to untreated cells or cells in the DNA 
damage checkpoint (24 h), there is an increase in the number of cells entering into 
mitosis following 48 -72 h treatment with 25 nM CPT.    
 
2.3.6. Cells are in Mitosis with Damaged DNA 
The third feature of checkpoint adaptation is entry into mitosis with 
damaged DNA.  It was demonstrated that CPT treated M059K cells activated the 
DNA damage checkpoint, arrested in the G2 phase of the cell cycle, and 
subsequently entered into mitosis.  Next was to test if the cells that entered into 
mitosis had damaged DNA.  Cells were examined by immunofluorescence 
microscopy for both phospho-ser10 histone H3 as well as γ-histone H2AX.  If 
cells were positive for phospho-ser10 histone H3 and positive for γ-histone H2AX 
following treatment with CPT for 48 h, then M059K cells were entering into 
mitosis with damaged DNA.      
Cells were either untreated or treated with 7.5 nM CPT for 48 h then fixed 
and stained for either γ-histone H2AX or phospho-ser10 histone H3.  
Immunofluorescence showed 3% of the untreated population were positive for γ-
histone H2AX, in comparison to 95% of the CPT treated population (Figure 8).  
In parallel, the number of cells positive for phospho-ser10 histone H3 was 5% in 
the untreated and 13% in the CPT treated population.  With 95% of cells  
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containing damaged DNA following CPT treatment and 13% of these cells in 
mitosis, these data indicate that a minimum of 8% of the treated cells that are in 
mitosis have damaged DNA.  Another feature of mitotic cells is chromosome 
condensation, which can be visualized by immunofluorescence microscopy.  It 
was observed that of the cells with a condensed 4',6-diamidino-2-phenylindole 
(DAPI) nuclear stain, 94% of them were also positive for γ-histone H2AX (Figure 
9). 
Together, this data suggest that M059K cells treated with 
pharmacologically relevant concentrations of CPT: 1) activate the DNA damage 
checkpoint and become arrested in the G2 phase of the cell cycle, 2) enter into 
mitosis, and 3) contain damaged DNA; suggesting that M059K cells undergo 
checkpoint adaptation when treated with CPT.       
 
2.3.7. Cells that Survive Mitosis following Treatment with CPT Acquire Micronuclei 
This thesis demonstrated that M059K cells fulfilled the three features that 
define checkpoint adaptation when exposed to CPT.  The next step was to address 
if there was evidence of genomic change in the cells that survive checkpoint 
adaptation by looking for micronuclei.  A micronucleus appears as a small 
membrane-bound nucleus that forms due to improper incorporation of acentric 
fragments or chromosomes into daughter nuclei during cell division (Fenech et 
al., 2011).  Micronuclei are commonly used as evidence of chromosome and/or 
genome  
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mutations caused by damaged DNA (Hovhannisyan et al., 2009).  An experiment 
was designed to look for M059K cells that survive checkpoint adaptation then 
examined these survivors for evidence of micronuclei.  Cells were either untreated 
or treated with 25 nM CPT over a period of 120 h.  The cells that survived CPT 
treatment were observed through phase contrast light microscopy.  I found that 
M059K surviving cells do contain micronuclei (Figure 10A).  In the untreated 
population, 1% of cells contained micronuclei.  Cells in the CPT treated 
population acquired one or more micronuclei increasingly over time with a total 
of 48% of the population containing micronuclei at 120 h (Figure 10B).  These 
data provide evidence that the cells that undergo checkpoint adaptation do have a 
rearranged genome.          
To confirm the observation of micronuclei by phase contrast light 
microscopy, cells were examined for a component of the nuclear membrane, 
lamin A/C.  Lamin A/C is a major protein of the nuclear lamina, therefore nuclei 
can be visualized by detecting this protein using immunofluorescence microscopy 
(Tanaka and Shimizu, 2000).  Cells were either untreated or treated with 25 nM 
CPT for 120 h then fixed and stained for lamin A/C, and observed by 
immunofluorescence microscopy.  Cells that were lamin A/C positive for 
micronuclei were counted.  In the untreated population 5% of cells were positive 
for micronuclei, whereas 47% were positive for micronuclei in the treated cells 
(Figure 11A and 11B).  These data provided evidence that some cells survive  
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checkpoint adaptation and the surviving cells often contain micronuclei, which is 
a characteristic of genomic rearrangement.     
 
2.4. Discussion 
Checkpoint adaptation is characterized by an arrest in the cell cycle, 
overcoming this arrest and then entering into mitosis despite the presence of 
damaged DNA (Toczyski et al., 1997).  Checkpoint adaptation has been 
demonstrated in a small number of human cancer cell lines including human bone, 
lymph and colon cancer following treatment with radiation or CPT (Syljuåsen et 
al., 2006; Rezacova et al., 2011; Kubara et al., 2012).  This thesis addressed 
whether checkpoint adaptation occurs in brain cancer cells, specifically the brain 
cancer cell line M059K.   
Brain cancer cells were chosen because checkpoint adaptation had not yet 
been reported in brain cancer cells.  There have however been reports on the 
possibility of mitotic catastrophe and mitotic slippage in cells from gliomas 
treated with genotoxic agents (Hirose et al., 2001; Holgersson et al., 2003; Riffell 
et al., 2009).  The glioblastoma also represents one of the deadliest forms of 
cancer and is difficult to treat.  And it has been reported to be sensitive to, and is 
treated using, the genotoxic agent CPT (Friedman et al., 1999; Raymond et al., 
2002b; Feun and Savaraj, 2008).  This research would also broaden the limited 
base of cell origins for which checkpoint adaptation has been reported.   
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The brain cancer cell line M059K was chosen because this is a well 
characterized cell line from a glioblastoma.  It is p53 deficient and has a sister cell 
line M059J, which lacks the DNA-PK catalytic subunit, both factors have made 
this a commonly researched cell line when exploring the DNA damage response 
(Virsik-Kopp et al., 2003; Block et al., 2004; Liu et al., 2008; Dejmek et al., 
2009).  Prior to this thesis work, there had been no reports of checkpoint 
adaptation in the M059K cell line.  There have however been demonstrations of 
M059K cells accumulating in a G2/M phase arrest following exposure to radiation 
or the radiomimetic drug bleomycin (Holgersson et al., 2003; Holgersson et al., 
2005).  This G2/M phase arrest was reported to be followed by a release from the 
G2/M block at 48 h, as determined by flow cytometry.  There was no exploration 
into the level of damaged DNA in cells that were released from this block.  
However it was suggested that the M059J cell line may have undergone mitotic 
catastrophe, which was not detected in the M059K cell line.  Another reason the 
M059K cell line was chosen is because it is a fibroblastic cancer cell, which could 
bridge the link between reports of checkpoint adaptation in cancer cells with the 
report suggesting checkpoint adaptation occurred in a non-cancerous fibroblast 
(Rezacova et al., 2011).  This would provide the opportunity to compare the 
effects of checkpoint adaptation in cancerous and non-cancerous cells when 
exposed to DNA damaging agents.           
To examine whether checkpoint adaptation occurs in brain cancer, the 
M059K brain cancer cell line was first introduced and characterized in our 
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laboratory.  Next, a concentration of the anticancer agent CPT was determined 
that M059K cells were sensitive to and that was also pharmacologically relevant.  
The effects of CPT treatment on the M059K cells were tested next.  The findings 
of this thesis research suggest that M059K cells do undergo checkpoint adaptation 
when treated with CPT, as they fulfil the three features that define checkpoint 
adaptation.  These data support that checkpoint adaptation is a universal 
characteristic in human cancer cells when treated with genotoxic agents.  One 
limitation of this research was the inability to look at a single cell for both 
markers of damaged DNA and mitosis.  In the future to address this, co-staining 
of cells with γ-histone H2AX and phospho-histone H3 may be done then observed 
by confocal microscopy that would allow for observation of signals from both 
antibodies in a single cell (Suzuki et al., 1997).  This thesis also reported the cells 
that survive checkpoint adaptation acquire micronuclei.  The presence of 
micronuclei in M059K cells following treatment, confirms these cells are entering 
mitosis with damaged DNA and the cells that survive mitosis, have a rearranged 
genome.   
In 2012, Crasta et al. suggested errors in mitosis can generate DNA breaks 
or chromosome pulverization followed by chromosome rearrangement, a 
phenomenon called chromothripsis (Crasta et al., 2012).  In this study both 
processes, DNA breakage and chromothripsis, resulted in the formation of cells 
containing micronuclei.  They also noted the DNA rearrangements and mutations 
acquired in micronuclei could be incorporated into the cellular genome, which 
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may result in cancer development.  This paper did not address checkpoint 
adaptation as a means for cellular entry into mitosis with damaged DNA.  But it 
could be speculated that if additional DNA breaks and whole genome 
rearrangements can occur from entry into mitosis with damaged DNA, then 
checkpoint adaptation may be the cause of this and may have grave implications 
on the genome of daughter cells and further cancer developments.    
Studies have established that nearly all the cells that undergo checkpoint 
adaptation eventually die (Syljuåsen et al., 2006; Kubara et al., 2012).  One study 
suggested that perhaps checkpoint adaptation is a biochemical pathway for cell 
death, distinct from apoptosis, whose biological significance is to eradicate cells 
that have irreparable damaged DNA (Vitale et al., 2011).  This argument must be 
considered.  However a study in 2012 reported that up to 2% of the cells that enter 
into mitosis with damaged DNA survive (Kubara et al., 2012).  The results of this 
thesis work suggest that these surviving cells contain micronuclei, indicating 
genomic rearrangement has occurred.  What becomes of the cells that survive 
checkpoint adaptation with rearranged genomes remains unknown.  However, the 
demonstration of micronuclei in surviving cells supports the prediction that cells 
surviving genotoxic treatments may be the source of tumour cells with major 
genomic rearrangements (Nakada et al., 2006; Nitiss, 2009).   
Overall, these data suggest M059K cells do undergo checkpoint adaptation 
when exposed to CPT, and that the cells that survive checkpoint adaptation have a 
rearranged genome.  We propose that checkpoint adaptation is a universal process 
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in cancer cells when treated with genotoxic agents, and the cells that survive 
checkpoint adaptation may be the source of secondary tumours.  This may also 
provide a potential explanation for chemoresistance of cancer and/or cancer 
relapse following treatment.  In the future it would be advantageous to explore the 
structure, life cycle and genome of surviving cells, to better understand what 
becomes of these cells.  It would be advantageous to look deeper into the level of 
DNA damage in surviving cells, which could potentially be done through assays 
such as the comet assay.  We could also look at the level of genome 
rearrangement in the surviving cells with techniques such as with karyotyping.  It 
would also be advantageous to explore whether we can exploit or prevent 
checkpoint adaptation from occurring.  Preliminary results indicate there may be 
chemical compounds that kill cells undergoing checkpoint adaptation more 
efficiently while they are in mitosis.  This would diminish the number of cells that 
survive checkpoint adaptation with rearranged genomes.  It may also be 
advantageous to see if we can prevent checkpoint adaptation from occurring by 
either inhibiting or eliminating biochemical pathways that allow or initiate 
checkpoint adaptation.  A broader understanding of checkpoint adaptation may 
have long term significance in improving or rerouting the current course of cancer 
treatment. 
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Chapter 3 
3.  The Effect of Phosphatase Inhibition upon Cells Treated with Genotoxic Agents 
 
3.1. Introduction 
The process of checkpoint adaptation is defined by three features in cells 
with damaged DNA: 1) cell cycle arrest, 2) entry into mitosis, 3) damaged DNA 
in mitotic cells (Toczyski et al., 1997).  In 2006, checkpoint adaptation was 
demonstrated in human osteosarcoma cells following treatment with radiation 
(Syljuåsen et al., 2006).  Checkpoint adaptation has since been demonstrated in 
the human colon carcinoma cell line HT-29 and lymphocytic leukemia cell line 
MOLT4, when treated with CPT and radiation (Rezacova et al., 2011; Kubara et 
al., 2012).  These data along with data in the brain cancer cell model suggest that 
checkpoint adaptation might be a common biological event in cancer cells.  The 
precise mechanism by which checkpoint adaptation occurs is unknown 
(Clemenson and Marsolier-Kergoat, 2009).     
Studies have shown that Chk1 is dephosphorylated at Ser317/345 in cells 
that have undergone checkpoint adaptation (Syljuåsen et al., 2006; Kubara et al., 
2012).  The phosphatase that dephosphorylates Ser317/345 of Chk1 is not known; 
however PP2A, PP1 and PP2C have been implicated as candidates for this 
dephosphorylation (den Elzen and O'Connell, 2004; Lu et al., 2005; Leung-
Pineda et al., 2006; Petersen et al., 2006; Landsverk et al., 2010).  I hypothesize 
that dephosphorylation of Chk1 at Ser345 is the mechanism that allows 
 72 
 
checkpoint adaptation to occur.  To test this hypothesis the HT-29 model, 
described in Kubara et al., 2012, was used.  Briefly, cells were treated with CPT 
for 48 h to induce damaged DNA, a time that cells would be undergoing 
checkpoint adaptation.  Cells were then treated with phosphatase inhibitors, to 
inhibit candidate phosphatases.  Cells were then analyzed for markers of 
checkpoint adaptation.  If Chk1 dephosphorylation at Ser345 is essential for cells 
to undergo checkpoint adaptation, then inhibiting this dephosphorylation should 
prevent checkpoint adaptation.   
Contrary to my hypothesis, this thesis reports that following treatment 
with CPT and a cytotoxic concentration of the potent PP2A inhibitor cantharidin, 
HT-29 cells became rounded and entered into mitosis, in a greater proportion than 
cells treated with CPT alone.   
 
3.2. Materials and Methods 
 
3.2.1. Cell Culture 
Human HT-29 cells (American Type Culture Collection) were maintained 
in RPMI 1640 (Invitrogen) medium supplemented with 10% decomplemented 
fetal calf serum (PAA Laboratories, Etobicoke, Ontario), 2 mM L-glutamine 
(Invitrogen), and 10mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid), pH 7.4.  Cells were grown at 37°C in 5 % CO2 and media were changed 
every second or third day.  HT-29 cells were plated at 500,000 cells/25 cm
2
 flask 
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and cultivated for 48 h prior to treatment.  The compound camptothecin (Sigma) 
was dissolved in dimethyl sulfoxide (DMSO) to a concentration of 10 mM and 
stored at -20C until further use.  The phosphatase inhibitors cantharidin, 
calyculin A, cyclosporin and okadaic acid were dissolved in dimethyl sulfoxide 
(DMSO) to a concentration of 1 mM, 0.5 mM or 0.1 mM, respectively and stored 
at -20C until use. 
 
3.2.2. Cytotoxicity Assay 
Cytotoxicity of each phosphatase inhibitor on HT-29 cells was measured 
by the microculture tetrazolium assay (MTT; (3-(4,5)- dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) (Mosmann, 1983). HT-29 cells were plated at 
7,000 cells/31 mm
2
 well and cultivated for 48 h prior to treatment.  Results were 
expressed as IC50, the compound concentrations that reduced by 50% the 
absorbance at 590 nm, compared to DMSO treated cells.  All measurements were 
done in triplicate at 24 h.   
 
3.2.3. Light Microscopy  
Cell images were taken with an Infinity 1.5 camera powered by Infinity 
Capture (Lumenera Corporation) software.  Live cells were detected by vital dye 
exclusion method using Amresco® Trypan Blue 0.4% solution (VWR, Canada).    
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3.2.4. Immunofluorescence Microscopy 
Cells were plated on glass coverslips at 50,000 cells/9.6cm
2
 well and 
cultivated for 48 h prior to treatment, then fixed in 3% formaldehyde for 20 min at 
room temperature.  Cells were permeabilized for 5 min in 0.2% Triton X-100 then 
incubated with either anti-histone gamma H2AX (No. 05-636, Millipore), or anti-
serine 10 phosphorylated histone H3 (No. 06-570, Millipore).  The secondary 
antibody Texas Red anti-rabbit (Jackson/Beckman Boulter) for anti-histone H3 
was added for 2 h.  Nuclei were stained with 300 nM 4',6-diamidino-2-
phenylindole (DAPI) in PBS for 15 min prior to mounting (Kubara et al., 2012).  
Cells were observed on a Zeiss microscope operated by Axiovision 3.1 software.  
Images were collected by Zeiss MR camera within the linear dynamic range.  
Images were prepared with Adobe Photoshop CS3 10.0 software.  Cells positive 
for phospho-histone H3 were counted.  Experiments were repeated at least twice.      
       
3.2.5. Statistics 
Graphing was done using Microsoft Excel 2007.  Data was collected and 
plotted as means ± standard deviations of the mean.  GraphPad Prism 5 software 
was used to generate dose response curves and estimate IC50.       
 
3.3. Results 
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3.3.1. Cytotoxicity of Candidate Phosphatase Inhibitors in HT-29 Cells 
To assess if the inhibition of phosphatases could affect checkpoint 
adaptation, first a cytotoxic concentrations of candidate phosphatase inhibitors 
was determined in HT-29 cells by the MTT assay.  This information provided a 
concentration with which to treat cells without killing them during the course of 
the experiment.  The MTT cytotoxicity assay was performed on HT-29 cells using 
the following phosphatase inhibitors: cantharidin, sodium fluoride and okadaic 
acid to inhibit PP2A; calyculin A to inhibit PP1 and PP2A; cyclosporin to inhibit 
PP2B.  Based on the MTT assay results, IC50 values were determined for each 
phosphatase inhibitor: cantharidin 1.9 µM, calyculin A 3.5 nM, sodium fluoride 
3.6 mM, okadaic acid 37 nM, cyclosporin 0.4 µM (Figure 12).  Based on these 
data, concentrations of 2.5 µM cantharidin and 5 nM calyculin A were used for 
subsequent experiments.  Due to time constraints, no further experiments were 
conducted on the effects of sodium fluoride, okadaic acid or cyclosporin treatment 
on checkpoint adaptation.           
 
3.3.2. HT-29 Cells Co-treated with CPT and Cantharidin or CPT and Calyculin A 
Acquire a Rounded Shape 
To assess if the inhibition of phosphatases could affect checkpoint 
adaptation, HT-29 cells were co-treated with CPT and phosphatase inhibitors.  
HT-29 cells were either untreated or treated with 25 nM CPT for 48 h to induce 
checkpoint adaptation.  The rounded cells were collected and removed by a  
 76 
 
 
 
 
 
 
 
 
 
 
 77 
 
mechanical shake-off, leaving behind only interphase cells.  The interphase cells 
were the test group because they would undergo checkpoint adaptation during the 
course of the experiment.  The interphase cells were either treated with DMSO (as 
a control) or 2.5 µM cantharidin.  After 2 h, a time sufficient for new rounded 
cells to appear, the culture was observed by light microscopy.  Interestingly, in the 
group co-treated with CPT and cantharidin, 95% of the cells became uniformly 
rounded.  In parallel, the untreated population had 2.6% rounded cells whereas the 
CPT alone treated cells had 21%.  The cells treated with cantharidin alone were 
not uniformly rounded, but appeared to be irregular in shape (Figure 13).   
The next step was to test the effect of treatment with calyculin A on 
checkpoint adaptation.  HT-29 cells were either untreated or treated with 25 nM 
CPT for 48 h to induce checkpoint adaptation.  The rounded cells were collected 
and removed by a mechanical shake-off, leaving behind only interphase cells.  
The interphase cells were either treated with DMSO or 5 nM calyculin A.  After 3 
h, the culture was observed by light microscopy.  In the group co-treated with 
CPT and calyculin A, 100% of the cells were uniformly rounded.  In parallel, only 
1.2% in the untreated population and 22% in the CPT alone treated population 
were rounded (Figure 14).  In contrast to my predicted result of blocking 
checkpoint adaptation, two phosphatase inhibitors were identified that increased 
the number of rounded cells in a culture that was first treated with CPT.  Further 
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experiments were conducted to confirm that these rounded cells were in mitosis 
following co-treatment with CPT and cantharidin.  Due to time constraints, no 
further experiments were conducted on the effect of co-treating cells with CPT 
and calyculin A. 
 
3.3.3. HT-29 Cells Treated with CPT and Cantharidin are in Mitosis 
To determine if the rounded cells co-treated with CPT and cantharidin 
were in mitosis, cells were examined for phospho-ser10 histone H3, a marker of 
cells in mitosis (Hendzel et al., 1997).  Cells were either untreated or treated with 
25 nM CPT for 48 h then either DMSO or 2.5 µM cantharidin was added to the 
sample for an additional 2 h.  Cells were fixed and stained for phospho-ser10 
histone H3 and analyzed by immunofluorescence microscopy (Figure 15A).  In 
the CPT-cantharidin sample, 65% of the cells were positive for phospho-ser10 
histone H3, whereas 18% were positive in the CPT only, 9% in cantharidin only 
and 2% in the untreated populations (Figure 15B).  These data confirmed the 
observation that co-treatment of cells with CPT and cantharidin causes HT-29 
cells to enter into mitosis at a much higher number than cells treated with CPT or 
cantharidin alone.   
 
3.4. Discussion 
Exposure to DNA damaging agents results in activation of the DNA 
damage checkpoint (Carr, 2002).  The DNA damage checkpoint initiates a  
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phosphorylation cascade of substrates including: Chk1 at Ser317/345, Cdc25 at 
Ser216, as well as phosphorylation of Cdk1 at Thr14 and Tyr15 (Liu et al., 2000; 
Zhao and Piwnica-Worms, 2001; Boutros et al., 2006).  With inhibitory 
phosphorylations present on Cdk1, the Cdk1/cyclin B complex is inactive, 
resulting in a G2-phase arrest of the cell cycle (Melo and Toczyski, 2002).  The 
precise biochemical process that enables cells to abrogate this DNA damage 
checkpoint and enter into mitosis with damaged DNA is unknown.  Previous 
studies have demonstrated that the cells are in mitosis, indicated by high Cdk1 
activity and phospho-histone H3 signals.  And strikingly, Chk1 is 
dephosphorylated at Ser345 in cells that have undergone checkpoint adaptation 
(Kubara et al., 2012).  Chk1 dephosphorylation has been identified as a candidate 
for the initiation of checkpoint adaptation (Syljuåsen et al., 2006; Kubara et al., 
2012).  However, it is not known if Chk1 dephosphorylation is causal for 
checkpoint adaptation.    
Previous studies have linked phosphatase inhibitors to the inhibition or 
delayed dephosphorylation of Chk1 at Ser317/345.  A study in 2006 demonstrated 
Chk1 dephosphorylation at Ser317/345 was inhibited using either the PP2A 
inhibitor okadaic acid or fostriecin, following exposure to the DNA damaging 
agent hydroxyurea (Leung-Pineda et al., 2006).  In addition, this study showed 
that PP2A depletion, through siRNA, also resulted in inhibition of Chk1 
dephosphorylation at Ser317/345.  This paper did not however explore what 
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effects phosphatase inhibitor treatment or Chk1 dephosphorylation had on the cell 
cycle or mitosis in cells that have been treated with a DNA damaging agent. 
Studies have been done on phosphatase inhibitor treatments resulting in 
abnormalities in the cell cycle however these studies were not done in the scope 
of checkpoint adaptation.  For example, cantharidin, okadaic acid and fostriecin 
have been shown to push cells prematurely into mitosis, often causing cell death 
(Cheng et al., 1998; Sakoff et al., 2004; Bonness et al., 2006).  Cheng and 
colleagues (1998) demonstrated that treating Chinese hamster ovary cells (CHO) 
with the PP2A inhibitors cantharidin, okadaic acid and fostriecin resulted in a 
mitotic block, and rounded cell morphology.  They also found that treatment over 
24 h with phosphatase inhibitors resulted in cell death via apoptosis.  Other 
studies have demonstrated that the PP1 and PP2A inhibitors okadaic acid and 
cantharidin inhibit cancer cell growth and cause cell death (Hart et al., 2004; 
Bonness et al., 2006; Lu et al., 2008).  As a result of this, phosphatase inhibition 
has been explored for its potential anticancer effects.  In 2009, Lu et al. explored 
the effects of treating U87MG cells with a synthesized PP2A inhibitor, LB-1.2, 
alone or in tandem with the common chemotherapeutic agents temolozolomide 
(TMZ) or doxorubicin (DOX).   They found that PP2A inhibition, through LB-
1.2, enhanced the effects of cancer chemotherapy when cells were co-treated with 
TMZ or DOX.  When mice were co-treated with LB-1.2 and either TMZ or DOX, 
Lu et al. reported delayed tumour growth or tumour regression, as well as delayed 
or absent recurrence of cancer cells.  In cell culture, they found that treatment of 
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U87MG cells with LB-1.2 in combination with either TMZ or DOX resulted in 
inappropriate entry of cells into mitosis, accelerating the timing of cell death.  
This study was not performed in the context of checkpoint adaptation; however, 
the increase in cell death was suggested to be due to mitotic catastrophe.    
To explore whether Chk1 dephosphorylation initiates checkpoint 
adaptation, it was addressed whether the inhibition of Chk1 dephosphorylation at 
Ser345 would inhibit checkpoint adaptation.  With the knowledge that PP2A 
inhibition has been shown to inhibit the dephosphorylation of Chk1 at Ser345 and 
cantharidin is an inhibitor of PP2A, HT-29 cells were treated with CPT (to induce 
checkpoint adaptation) and then cells were treated with cantharidin.  The 
concentration of cantharidin used in these assays was selected based on the results 
of the MTT cytotoxicity assay, this was also a concentration demonstrated to 
inhibit PP2A in human cells (Cairns et al., 1994).  I hypothesized that if Chk1 
dephosphorylation is an essential step in checkpoint adaptation, then treating cells 
with cantharidin should inhibit checkpoint adaptation.  Our research data 
indicated that co-treatment of cells with CPT and cantharidin or CPT and 
calyculin A, resulted in rounded cells.  Of the cells co-treated with CPT and 
cantharidin, 65% were positive for phospho-ser10 histone H3, confirming they 
were in mitosis.  Whereas only 18% of the cells treated with CPT alone were 
positive for phospho-ser10 histone H3.  Although 35% of the rounded cells were 
not positive for phopho-ser10 histone H3, as would have been expected from the 
rounded cell morphology, phospho-ser10 histone H3 is the more precise marker 
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for determining cells in mitosis.  The remainder of the cells may have been 
undergoing a different cellular process, such as apoptosis; however, further 
investigation would need to be to done.  These results indicated that PP2A 
inhibition caused more cells to be in mitosis, following treatment with CPT.  This 
increase in the number of cells undergoing checkpoint adaptation upon PP2A 
inhibition was an unanticipated result and lead to the conclusion that other 
pathways might be involved in the regulation of checkpoint adaptation.       
  Recent studies have indicated that Greatwall kinase (Gwl) is a factor in 
the regulation of mitosis through its inhibition of PP2A (Vigneron et al., 2009; 
Gharbi-Ayachi et al., 2010; Mochida et al., 2010; Boke and Hagan, 2011).  These 
studies have reported that PP2A is believed to antagonize the activity of the 
mitotic protein kinase Cdk1; in mitosis Cdk1 is active and PP2A is inactive.  One 
study reported that Gwl inhibits PP2A (Figure 16), causing at least four major 
MPF substrates (Cdc2, Cdc27, MAPK, and Erp1/Emi2) to remain phosphorylated 
and thereby maintaining the mitotic state of cells (Vigneron et al., 2009).  It was 
also reported that PP1/PP2A inhibitors, such as okadaic acid, were able to rescue 
the phenotype induced by Gwl inactivation.  Subsequent studies reported that Gwl 
phosphorylates and activates the two proteins Arpp19 and Ensa, which are potent 
inhibitors of PP2A (Gharbi-Ayachi et al., 2010; Mochida et al., 2010).  These 
studies suggest that the results obtained in this study, a massive number of cells 
entering into mitosis even though they contain damaged DNA, is due to PP2A 
inhibition through cantharidin.  This result indicates that the inhibition of PP2A is  
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perhaps a prevailing biochemical process over the precise process that results in 
checkpoint adaptation or accelerates the process that results in checkpoint 
adaptation.   
To confirm that PP2A inhibition resulted in a larger proportion of cells 
undergoing checkpoint adaptation, it would need to be confirmed that the cells 
that were in mitosis following CPT and cantharidin treatment still contain 
damaged DNA.  However, the results of this experiment suggest the cells that 
entered into mitosis do have damaged DNA based on two facts: 1) Prior to 
cantharidin treatment, cells were treated with CPT for 48 h, conditions that have 
been shown to result in entry into mitosis with damaged DNA, and 2) PP2A 
inhibition results in inefficient DNA repair and causes cells to be hypersensitive 
to DNA damage (Chowdhury et al., 2005).  In the future, a different marker for 
the detection of DNA damage would be needed.  The marker used in previous 
studies of checkpoint adaptation (including my own) γ-H2AX, is 
dephosphorylated by PP2A upon DNA repair, and as such, inhibition of PP2A 
could potentially give a false positive result for the presence of DNA damage.  An 
example of an alternative method for the detection of damaged DNA is the comet 
assay (Collins, 2004).       
To confirm that PP2A inhibition resulted in a larger proportion of cells 
undergoing checkpoint adaptation, it would also be necessary to confirm that the 
cantharidin treatment only inhibited PP2A in cells.  Phosphatase inhibitors are 
often responsible for the inhibition of more than one phosphatase (Leung-Pineda 
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et al., 2006; Pereira et al., 2011).  For example, cantharidin can also inhibit PP4 
and PP6 at concentrations that inhibit PP2A, and inhibit PP1 at concentrations 
above those which inhibit PP2A.  It would therefore need to be confirmed that the 
cantharidin treatment inhibited PP2A alone.  The effects of PP2A inhibition could 
be confirmed by using RNAi.  PP2A knockdown would result in the depletion of 
PP2A, at which point the effects on checkpoint adaptation could be observed.   
The results of this research indicate that PP2A inhibition, through 
cantharidin treatment, pushes cells into mitosis when co-treated with CPT.  
Treatment of cells with CPT for 48 h primes cells for entry into mitosis as 
evidenced by the accumulation of 4N DNA, high cyclin B levels and low Cdk1 
activity (Kubara et al., 2012).  Treatment of cells with the PP2A inhibitor 
cantharidin possibly pushes these primed cells into mitosis through the Gwl 
pathway.  A remaining question is whether PP2A inhibition was successful in 
preventing the dephosphorylation of Chk1 at Ser345.  If Chk1 dephosphorylation 
was not inhibited with PP2A inhibition, then Chk1 is dephosphorylated by 
another protein phosphatase.  The other candidate phosphatase proposed to be 
involved in Chk1 dephosphorylation at Ser345 is PP1.  If Chk1 is 
dephosphorylated following cantharidin treatment, then PP1 may be the 
phosphatase responsible for Chk1 dephosphorylation.  In the future, treatment 
with the PP1 phosphatase inhibitor tautomycin could be explored, to determine if 
PP1 inhibition has an effect on checkpoint adaptation.  However, if PP2A 
inhibition was successful in preventing the dephosphorylation of Chk1 at 
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Ser317/345, then it can be assumed that the effect of PP2A inhibition on the 
initiation of mitosis through the Gwl pathway is independent of or bypasses the 
precise biochemical process that results in checkpoint adaptation.  Cells were also 
co-treated with calyculin A, an inhibitor of PP1 and PP2A with equal potency, 
which also resulted in rounded cells following CPT treatment.  This result does 
not exclude PP1 as a potential candidate for the dephosphorylation of Chk1, as 
entry into mitosis through PP2A inhibition and the Gwl pathway, may be a 
prevailing biochemical process.   
To address whether Chk1 dephosphorylation at Ser345 is important in the 
initiation or maintenance of checkpoint adaptation, exploration into pathways that 
prevent Chk1 dephosphorylation, aside from PP2A inhibition would be necessary.  
One way to do this may be to produce Chk1 constructs with altered Ser317/345 
regulatory sites.  This may be done through the use of a previously published, C-
terminal domain truncated, permanently active Chk1 variant, containing only the 
amino acids 1-289 (Ferry et al., 2011).  Another option for altering the Chk1 
Ser317/345 regulatory sites may be to replace the serine317/345 residues of Chk1 
with negatively charged glutamate residues, which might result in a permanently 
active Chk1.  This could then permit us to explore what effects a permanently 
active Chk1 has on checkpoint adaptation.    
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Chapter 4 
4.  Review of Thesis 
Progression through the cell cycle is a carefully regulated and coordinated 
process.  Cell cycle regulation has been conserved from yeast to mammals and 
ensures the formation of genetically identical progeny cells (George, 2003).  Cells 
are equipped with a molecular system composed of sensors, transducers and 
effectors called the DNA damage checkpoint.  The DNA damage checkpoint 
prevents the proliferation of cells with damaged DNA in order to maintain 
genomic integrity (Melo and Toczyski, 2002).  Until recently, the two main 
outcomes of the DNA damage checkpoint in human cells were believed to be: 1) 
checkpoint recovery, in which cell cycle arrest is followed by DNA repair and re-
entry into mitosis, 2) apoptosis, in which the DNA damage could not be repaired 
resulting in programmed cell death (Sancar et al., 2004).   
Checkpoint adaptation has recently been proposed as a third possible 
outcome following the initiation of the DNA damage checkpoint.  In 1993 
checkpoint adaptation was originally reported in Saccharomyces cerevisiae, 
although not called checkpoint adaptation at that time.  It was reported as the 
ability of yeast cells to divide following a checkpoint arrest, despite the presence 
of irreparable chromosome damage (Sandell and Zakian, 1993).  Checkpoint 
adaptation is now defined by three features in cells with damaged DNA: 1) cell 
cycle arrest, 2) entry into mitosis, 3) damaged DNA in mitotic cells (Toczyski et 
al., 1997).  In 2006, Syljuåsen et al. reported that checkpoint adaptation also 
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occurred in human cancer cells.  In this study, human bone cancer cells were 
irradiated to damage the DNA (Syljuåsen et al., 2006).  Following exposure to 
radiation, the cells entered into a DNA damage checkpoint arrest.  The treated 
cells were able to overcome this cell cycle arrest and enter into mitosis despite the 
presence of damaged DNA.  Since 2006, checkpoint adaptation has been clearly 
demonstrated in both human colon carcinoma and lymphocytic leukemia cells 
(Rezacova et al., 2011; Kubara et al., 2012).  Checkpoint adaptation has also been 
suggested to occur in at least two other cancer cell lines including a non-
cancerous cell line (Wang et al., 2008; Rezacova et al., 2011).  Checkpoint 
adaptation has since been hypothesized to be a universal event in cancer cells 
when exposed to DNA damaging agents.   
Prior to this thesis work, checkpoint adaptation had not yet been 
demonstrated in a brain cancer cell line.  Within the literature, however, several 
laboratories have described cell phenotypes that suggest checkpoint adaptation 
might occur in human brain cancer cells.  For example, M059K cells, the cell line 
that was used for this thesis work, have been reported to undergo mitotic 
catastrophe or form giant cells after genotoxic treatments (Hirose et al., 2001; 
Holgersson et al., 2003).  There have also been reports on M059K or M059J cells 
entering into a G2/M phase block that was later released, following genotoxic 
treatments (Holgersson et al., 2003; Holgersson et al., 2005).  However, none of 
these reports explored the criteria for checkpoint adaptation as described by 
Toczyski et al. in 1997.  A portion of this thesis was dedicated to determine if 
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checkpoint adaptation occurs in human brain cancer cells.  This information is 
important, because if we understand the biochemical basis of checkpoint 
adaptation in major cancers, such as brain cancer, we will likely be able to 
propose methods to improve treatments.        
This thesis reports that brain cancer cells, treated with the anticancer agent 
CPT, undergo checkpoint adaptation.  Following 48 h treatment with CPT, 
M059K cells exhibit the three criteria of checkpoint adaptation (Toczyski et al., 
1997).  Using flow cytometry and Western blotting, it was demonstrated that CPT 
treated cells enter into a G2 phase arrest of the cell cycle.  Thereafter the cells 
enter into mitosis with damaged DNA, as demonstrated with phospho-histone H3 
and γ-H2AX immunofluorescence microscopy.  An important finding from this 
study was that the M059K cells that survive checkpoint adaptation acquire 
micronuclei, a marker for chromosome or genome damage (Hovhannisyan et al., 
2009).  At 120 h CPT treatment, approximately half the cell population contained 
one or more micronuclei.  The presence of micronuclei in cells that have 
undergone checkpoint adaptation provides evidence that the survivors of mitosis 
with damaged DNA have a rearranged genome.   
Glioblastomas are one of the deadliest forms of cancer due to their high 
proliferative rate, aggressive invasiveness and insensitivity to radio or 
chemotherapeutic treatments (Alves et al., 2011).  These factors have resulted in 
an urgent need to improve brain cancer treatments.  The demonstration of 
checkpoint adaptation in cells from a glioblastoma provides us with a better 
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understanding of how this cancer reacts to clinically relevant amounts of the anti-
cancer agent CPT.  With the knowledge that brain cancer cells undergo 
checkpoint adaptation, we may now focus our attention on altering the course of 
checkpoint adaptation.  One way to inhibit checkpoint adaptation may be through 
the use of Cdk1 inhibitors (Figure 17).  This will enable us to continue to utilize 
the cytotoxicity of genotoxic treatments however Cdk1 inhibition may enable us 
to prevent entry into mitosis with damaged DNA.  Another method may be to 
exploit checkpoint adaptation through the use of Chk1 inhibitors.  Treating DNA 
damaged cells with a Chk1 inhibitor, would eliminate the DNA damage response 
(Cahuzac et al., 2010).   Eliminating the DNA damage response would then 
accelerate entry into mitosis with damaged DNA as well as accelerate a mitosis-
linked cell death.  The demonstration of checkpoint adaptation in a cancerous 
fibroblastic cell line also provides us with an opportunity to explore if checkpoint 
adaptation also occurs in human non-cancerous cells exposed to genotoxic agents.  
Non-cancerous epithelial cells are difficult to cultivate in a laboratory, therefore 
demonstrating that checkpoint adaptation occurs in cancerous fibroblastic cells 
provides us with a setting in which we can test if non-cancerous fibroblastic cells 
also undergo checkpoint adaptation.  Investigating whether non-cancerous 
fibroblastic cells undergo checkpoint adaptation may provide insight on how 
every cell, cancerous or not, reacts when exposed to DNA damaging agents.      
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The report of checkpoint adaptation in brain cancer cells not only provides 
us with knowledge on how brain cancer cells react to anti-cancer treatments it also 
expands our still limited knowledge of checkpoint adaptation.  The demonstration 
of checkpoint adaptation in the M059K cell line, adds a new origin and tumour 
type (brain and glioma), to the short list of origins and tumour types in which 
checkpoint adaptation has been demonstrated.  The demonstration of checkpoint 
adaptation provides support that checkpoint adaptation is a universal event in 
cancer cells following treatment with genotoxic agents. 
The presence of micronuclei in brain cancer cells that have undergone 
checkpoint adaptation suggests that checkpoint adaptation results in cells with 
genomic rearrangement.  In 2012, Crasta et al. suggested errors in mitosis can 
generate DNA breaks or chromosome pulverization followed by chromosome 
rearrangement, a phenomenon called chromothripsis.  In this study both 
processes, DNA breakage and chromothripsis, resulted in the formation of cells 
containing micronuclei (Crasta et al., 2012).  They also noted that the DNA 
rearrangements and mutations acquired in micronuclei could be incorporated into 
the genome, which may result in further cancer development.  The presence of 
micronuclei in brain cancer cells that have undergone checkpoint adaptation may 
provide a potential explanation for the insensitivity or resistance of brain cancer to 
genotoxic treatments.  It may also provide an explanation for cancer relapse or the 
formation of secondary tumours (Nakada et al., 2006; Wang et al., 2008; Kuntz 
and O'Connell, 2009; Nitiss, 2009).  One explanation for cancer cell resistance, 
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following genotoxic treatment, is the production of genomic mutations or 
rearrangements that enable cancer cells to survive therapy.  The cells that survive 
therapy then proliferate resulting in a population of cells resistant to therapy 
(Kerbel, 1997; Gottesman et al., 2002).  The presence of micronuclei in cells is a 
marker for genomic mutations or genomic rearrangements (Hovhannisyan et al., 
2009).  The demonstration of micronuclei in cells that have undergone checkpoint 
adaptation, suggests that checkpoint adaptation may be the link between genomic 
mutations that lead to cancer cell resistance.  Future research directions may 
include further exploration of the cells that survive checkpoint adaptation; such as 
the proliferation rates, cell viability, and chromosome or genome stability of these 
surviving cells, to understand better what becomes of these surviving cells.    
Mitotic catastrophe, or aberrant mitosis ending in cell death, is a process 
that has been suggested in many cell types, including brain cancers.  Checkpoint 
adaptation, entry into mitosis with damaged DNA, has also been demonstrated in 
a few cell types, including brain cancer cells.  It has been suggested that mitotic 
catastrophe and checkpoint adaptation may be connected (Bartek and Lukas, 
2007; Vakifahmetoglu et al., 2008).  The demonstration of checkpoint adaptation 
in brain cancer cells, along with the previous demonstrations of mitotic 
catastrophe in brain cancer cells supports the hypothesis that these two processes 
may be related.  In the future it may be advantageous to explore the potential link 
between mitotic catastrophe and checkpoint adaptation.  
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The precise biochemical process that allows cells to abrogate the DNA 
damage checkpoint, even though they still contain damaged DNA remains to be 
understood.  However, there have been reports that the cells that have undergone 
checkpoint adaptation have dephosphorylated Ser317/345 residues of Chk1 
(Syljuåsen et al., 2006; Kubara et al., 2012).  Chk1 dephosphorylation at 
Ser317/345 has been hypothesized to be the biochemical event that regulates 
checkpoint adaptation.  This event would require the activity of protein 
phosphatases.  The remaining portion of this thesis was dedicated to testing the 
relationship between checkpoint adaptation and protein phosphatase activity.  
HT-29 cells were treated with CPT for 48 h, conditions that result in 
checkpoint adaptation.  Then these cells, which were primed to undergo 
checkpoint adaptation, were treated with cytotoxic concentrations of the 
phosphatase inhibitor cantharidin and calyculin A.  Cantharidin inhibits protein 
phosphatase PP2A, and calyculin A inhibits both PP2A and PP1.  Both PP2A and 
PP1 have been suggested to be involved in Chk1 dephosphorylation at Ser345 
(den Elzen and O'Connell, 2004; Leung-Pineda et al., 2006; Petersen et al., 2006; 
Landsverk et al., 2010).  If Chk1 dephosphorylation at Ser345 is an essential step 
in initiating checkpoint adaptation, then preventing this step, would prevent 
checkpoint adaptation.  In contrast to my prediction, that cantharidin or calyculin 
A treatment would block checkpoint adaptation, it resulted in a massive and rapid 
entry of cells into mitosis.   
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Although this result was contrary to my predication, it suggested that 
another major pathway may participate in checkpoint adaptation.  Recent studies 
suggest that PP2A inhibition and entry into mitosis is linked to the Greatwall 
(Gwl) pathway.  Gwl is a protein kinase that regulates mitosis through its 
inhibition of PP2A (Vigneron et al., 2009; Gharbi-Ayachi et al., 2010; Mochida et 
al., 2010; Boke and Hagan, 2011).  By inhibiting PP2A, through treatment with 
cantharidin and calyculin A, the cells were pushed into mitosis presumably with 
damaged DNA (see Figure 16).  I hypothesize then that the inhibition of PP2A is 
a prevailing biochemical process over the biochemical process that results in 
checkpoint adaptation, or bypasses it. 
This finding demonstrated that in the future we may be able to alter the 
course of checkpoint adaptation; in this case it was accelerated and enhanced.  
This knowledge may eventually lead to improvements in cancer treatments.  
Future directions include exploring if PP2A inhibition was successful in 
preventing the dephosphorylation of Ser317/345 of Chk1, and looking further into 
a potential mechanism that may be able to inhibit cells from entering into mitosis 
with damaged DNA, such as Cdk1 inhibition. 
 
4.1. Thesis Conclusions 
The purpose of this thesis was two-fold 1) to determine if checkpoint 
adaptation occurs in the brain cancer cell line M059K following treatment with 
the genotoxic agent CPT and 2) to test the relationship between checkpoint 
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adaptation and protein phosphatase activity.  This was done to provide evidence 
that checkpoint adaptation is a universal feature in cancer cells exposed to 
genotoxic agents and to better understand the biochemical basis of checkpoint 
adaptation.  A better understanding of the biological significance and biochemical 
process of checkpoint adaptation may eventually provide us with an opportunity 
to alter the fate of checkpoint adaptation.  Altering the course of checkpoint 
adaptation may eventually have long term significance for improving current 
cancer treatment.  Based on the work presented in this thesis, the following 
conclusions were reached: 
 
1. Following treatment with cytotoxic concentrations of CPT, M059K cells 
enter into a DNA damage induced G2 phase arrest of the cell cycle, and 
contain the active form of Chk1 (P-Ser345).   
 
2. Following CPT treatment, M059K cells become rounded and enter into 
mitosis with damaged DNA, therefore M059K cells do undergo 
checkpoint adaptation. 
 
 
3.  Following treatment with CPT, M059K cells acquire micronuclei, an 
indicator of genome damage.  This provides evidence that the cells that 
survive checkpoint adaptation contain a rearranged genome.      
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4. HT-29 cells treated with CPT, at conditions that result in checkpoint 
adaptation, followed by treatment with cytotoxic concentration of the 
phosphatase inhibitor cantharidin, rapidly enter into mitosis. 
 
5. The entry of cells into mitosis following treatment with CPT and 
cantharidin is likely due to inhibition of protein phosphatase PP2A. 
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